

(19)



(11)

EP 2 385 375 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
09.11.2011 Bulletin 2011/45

(51) Int Cl.:
G01N 33/92 (2006.01) G01N 33/58 (2006.01)
G01N 33/533 (2006.01) G01N 33/72 (2006.01)

(21) Application number: **10177671.4**

(22) Date of filing: **21.03.2005**

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

- **Huber, Andrew, Henry**
Encinitas, CA 92024 (US)
- **Kampf, James, Patrick**
San Diego, CA 92130 (US)
- **Zhu, Baolong**
San Diego, CA 92122 (US)
- **Kwan, Thomas**
San Diego, CA 92122 (US)

(30) Priority: **22.03.2004 US 555224 P**

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:
05731342.1 / 1 728 080

(74) Representative: **Becker Kurig Straus**
Patentanwälte
Bavariastrasse 7
80336 München (DE)

(27) Previously filed application:
21.03.2005 EP 05731342

(71) Applicant: **FFA Sciences, LLP**
San Diego, CA 92121 (US)

Remarks:

This application was filed on 20-09-2010 as a divisional application to the application mentioned under INID code 62.

(72) Inventors:
• **Kleinfeld, Alan, Marc**
La Jolla, CA 92037 (US)

(54) **Development and use of fluorescent probes of unbound analytes**

(57) A method for high throughput screening of probes is described. These probes are useful for characterization and measurement of unbound metabolites in a fluid sample, particularly characterization and measurement of levels of unbound free fatty acids. By practice of the disclosed invention, a profile of unbound metabolites can be determined for an individual which can be used to determine the individual's relative risk for disease such as stroke, cardiac disease and cancer.




FIG. 1

EP 2 385 375 A2

DescriptionBackground of the Invention5 Field of the Invention

[0001] The field of the invention relates to high throughput screening methods to provide specific probes that measure levels of unbound analytes, including unbound free fatty acids and other unbound metabolites. Also disclosed are probes obtained with the high throughput screening methods and the use of a combination of probes to determine an unbound free fatty acid profile or more generally an unbound metabolite profile for an individual.

Description of the Related Art

15 **[0002]** For purposes of the present disclosure, fatty acids are non esterified carboxylated alkyl chains of 1-30 carbons atoms which may exist as neutral (e.g. protonated, sodium or potassium salt) or ionic species, depending upon the pH and conditions of the aqueous media. Free fatty acids (FFA) are equivalent to fatty acids and both terms refer to the totality of FFA including those in aqueous solution as monomers plus those that are not in solution (for example bound to other macromolecules (proteins, membranes), cells or part of an aggregate of FFA (micelles, soaps and other more complex aggregates). FFA present as monomers in aqueous solution (either charged or neutral) are referred to as unbound free fatty acids (FFAu). For the purposes of the present disclosure, probes are fluorescently labeled proteins that upon binding an analyte, such as a FFAu, reveal a measurable change in fluorescence.

20 **[0003]** For purposes of the present disclosure, metabolites are physiologically important molecules whose molecular weight is approximately 2000 Da or less. These include molecules that occur naturally in the course of human or animal physiology or pathophysiology, and drug molecules and their metabolic products and nutrient molecules and their metabolic products. Similar to FFA and depending upon their solubility, a fraction of each metabolite is present as monomers in aqueous solution (either charged or neutral). We refer to this fraction as the unbound metabolite. For the purposes of the present disclosure, probes are fluorescently labeled proteins that reveal a measurable change in fluorescence upon binding to unbound metabolite.

25 **[0004]** For the purposes of the present disclosure, the term "lipid" is taken to have its usual and customary meaning and defines a chemical compound which is most soluble in an organic solvent but has some level of solubility in the aqueous phase (the fraction that is unbound). Accordingly, a "lipid-binding protein" includes any protein capable of binding a lipid as lipid is defined herein.

30 **[0005]** Levels of unbound molecules, such as for example lipids, hormones and metabolic products, can provide information diagnostic of health and disease when measured in appropriate human or animal fluids. It is increasingly apparent that determination of the unbound (a.k.a 'aqueous phase' or 'free') concentration of such molecules provides critical information about physiologic homeostasis. Many metabolites are hydrophobic molecules with low aqueous solubility and unbound concentrations that are much lower than their "total" concentration, where the bulk of the "total" may be bound to proteins or cells.

35 **[0006]** Intracellular lipid binding proteins (iLBP) are a family of low-molecular weight single chain polypeptides. There are four recognized subfamilies. Subfamily I contains proteins specific for vitamin A derivatives such as retinoic acid and retinol. Subfamily II contains proteins with specificities for bile acids, eicosanoids, and heme. Subfamily III contains intestinal type fatty acid binding proteins (FABPs) and Subfamily IV contains all other types of fatty acid binding protein (Hauerland, et al. (2004) Progress in Lipid Research vol. 43: 328-349). The entire family is characterized by a common 3-dimensional fold. Ligand binding properties of the different subfamilies overlap considerably. The wild type proteins of subfamilies I (Richieri et al (2000) Biochemistry 39:7197-7204) and II both bind fatty acids and those of subfamily II bind fatty acids as well as their native ligands. Moreover, single amino acid substitutions are able to interconvert the ligand binding properties of proteins of subfamilies I and II (Jakoby et al (1993) Biochemistry 32:872-878).

40 **[0007]** U.S. Patent Nos. 5,470,714 and U.S. 6,444,432, which are incorporated herein by reference, describe probes for the determination of unbound free fatty acids (FFAu). These probes were constructed using either native or mutant forms of proteins from the iLBP family. As discussed above, this family includes FABPs (Banaszak et al (1994) Adv. Protein Chem. 45:89-151; Bernlohr et al (1997) Ann. Rev. Nutrition, 17: 277-303). FABPs are intracellular proteins of approximately 15 kDa molecular weight and have a binding site that binds 1 or 2 FFA. Unfortunately, there is currently no way to determine the concentrations of different FFAu in mixtures of FFAu. Similarly, there are no general methods for determining the unbound concentrations of other important metabolites such as, for example other lipids, hormones, and drugs. This is largely due to the low concentration at which these components are present and their often poor solubility properties in aqueous solutions.

45 **[0008]** Unfortunately, despite the availability of protein structures and co-complex structures with ligands of interest, existing state of the art of molecular theory is not sufficient to design probes with the desired specificity and sensitivity

de novo. Thus, extensive experimentation is typically required to find protein probes that not only bind with the desired specificity, but also produce a measurable signal indicative of ligand binding. Improving specificity and signaling through a completely random mutational strategy is not practical even for a small protein such as an FABP because a) there are 20^{131} possible mutants for a 131 residue FABP, and b) testing even a single probe using established state of the art methods requires extensive time (at least 2 weeks/probe) for purification, reaction chemistry and probe fluorescence response characterization.

[0009] Even if a more modest library of mutants is generated through random mutagenesis in specific regions of the protein, a method is needed to rapidly generate and screen the thousands of resulting mutant probes. Each mutant needs to be produced, and chemically reacted with a fluorescent group, in sufficient quantity to enable the measurement of its sensitivity and selectivity for many different ligands. It is also critical that the probes be as free as possible of contaminating proteins, unreacted fluorophore, and any other compounds that might interfere with sensitive fluorescence measurements. The development of a rapid, automated method for measuring and comparing probe responses to ligand is also critical. Embodiments of the invention described here satisfy these needs by disclosing "high throughput" methods for the rapid a) generation of large numbers of probes and the b) screening and characterization of these probes. An important aspect of this invention is that it allows the previous necessary and very time consuming step of characterization of ligand binding to the protein to be omitted; only the probe itself is characterized. This is important not only for the avoidance of the protein characterization step but also because the properties of the probe are often not predictable from the ligand-protein binding characteristics. For example, different proteins can have very similar binding affinities but the fluorescence response of their derivative probes can be quite different.

Summary of the Invention

[0010] Embodiments of the invention are directed to high throughput methods for generating and screening of probes. Embodiments of the method may include one or more of the following steps:

generating polynucleotides encoding a protein library which includes an assortment of proteins which are mutations of a template protein capable of binding to a molecule of interest participating in a binding reaction;

expressing the proteins;

purifying the proteins by binding to a solid matrix;

associating the matrix bound proteins with fluorophores to produce probes;

retrieving the probes from the solid matrix; and

screening the probes in a fluorometer in the presence and absence of the molecule.

[0011] In preferred embodiments, the template protein is non-enzymatic and the molecule is an unbound metabolite. Preferably, the template protein is an intracellular Lipid Binding Protein (iLBP). In some highly preferred embodiments, the template protein is a Fatty Acid Binding Protein (FABP).

[0012] Preferably, the template protein includes a cleavable or noncleavable affinity tag. In some preferred embodiments, the template protein includes a poly-histidine affinity tag and the solid matrix includes an immobilized metal chelate. In alternate preferred embodiments, the solid matrix includes an antibody specific for an epitope that lies outside the molecule binding region of the template protein.

[0013] In preferred embodiments, the fluorophore preferentially reacts with cysteine and lysine amino acid sidechains. More preferably, the fluorophore is acrylodan.

[0014] In preferred embodiments, the unbound metabolite is an unbound free fatty acid. More preferably, the free fatty acid is complexed with a carrier macromolecule which provides clamping of a level of unbound free fatty acid. Yet more preferably, the carrier macromolecule is albumin. Embodiments of the invention are also directed to probes produced by the high throughput screening methods described above.

[0015] Some preferred embodiments include comparing a ratio of fluorescence intensities of the probe at a first wavelength with that of the probe at a second wavelength in the presence and absence of the molecule.

[0016] In some preferred embodiments, probes with desirable characteristics are identified with the following steps:

determining a value for R by the following formula:

$$R = F_{\lambda 1}/F_{\lambda 2}$$

5

wherein $F_{\lambda 1}$ is a measured fluorescence intensity (intensity of a sample with probe present minus intensity of the sample without probe present) at a first emission wavelength, $F_{\lambda 2}$ is a measured fluorescence intensity (intensity of a sample with probe present minus intensity of the sample without probe present) at a second emission wavelength; measuring the difference between R in the presence and absence of the molecule by the formula

10

$$\Delta R = R_{+\text{molecule}} - R_0$$

15

wherein $R_{+\text{molecule}}$ is the ratio value for the measurement done in the presence of the molecule and R_0 is the ratio value for the measurement done in the absence of the molecule; and comparing ΔR for the probe to $\Delta R_{\text{reference}}$ for a standard.

20

[0017] Preferably, the standard is the template protein used to generate mutations for the high throughput screening. In some preferred embodiments, the standard is ADIFAB or ADIFAB2.

25

[0018] In some preferred embodiments, $\Delta R/\Delta R_{\text{reference}}$ is > 0.1 and the molecule is a fatty acid. In alternate preferred embodiments, the $\Delta R/\Delta R_{\text{reference}}$ is < 0.1 for unbound fatty acids but is > 0.1 for an unbound metabolite that is not a fatty acid.

[0019] Embodiments of the invention are directed to methods for high throughput generating and screening of probes which may include one or more of the following steps:

30

generating a library of polynucleotides encoding affinity-tagged FABP muteins from a template FABP;

expressing the FABP muteins and tags;

purifying the FABP muteins by binding the tags to a solid matrix;

35

associating the FABP muteins with fluorophores to produce probes;

reformatting the probes in an array;

40

adding a sample which includes an unbound metabolite to be tested;

scanning the probes in a fluorometer in the presence and absence of the unbound metabolite to be tested; and

comparing fluorescence of the probes in the presence and absence of the unbound metabolite.

45

[0020] In some preferred embodiments, the unbound metabolite is an unbound free fatty acid.

[0021] In preferred embodiments, associating the FABP muteins with the fluorophores is performed while the FABP muteins are bound to the solid matrix. In preferred embodiments, the fluorophore preferentially reacts with cysteine and lysine amino acid sidechains. More preferably, the fluorophore is acrylodan.

50

[0022] In some alternate embodiments, the following steps may be performed:

washing the bound FABP muteins;

removing the FABP muteins from the solid matrix; and

55

reacting the unbound FABP muteins with fluorophores to produce probes.

[0023] In preferred embodiments, the high throughput screening methods may include comparing a fluorescence

index, which may include changes in intensity, polarization and/or lifetime of the probe in the presence and absence of the unbound metabolite to be tested. Comparing the fluorescence index may also include comparing the fluorescence index of the probe at a first wavelength with that of the probe at a second wavelength in the presence and absence of the unbound FFA to be tested.

5 **[0024]** In preferred embodiments, the sample also includes a carrier macromolecule, whereby the carrier macromolecule complexes with the unbound metabolite to provide clamping. More preferably, the carrier macromolecule is albumin, lipid binding proteins, lipid vesicles or methyl-beta-cyclodextrin.

[0025] Embodiments of the invention are directed to probes produced by the high throughput screening methods described above. Preferred embodiments of the invention are directed to one or more probes which are those listed in
10 Tables 3-7.

[0026] Embodiments of the invention are directed to methods to determine the concentration of unbound bilirubin in body fluids of a mammal which may include withdrawing a body fluid from the mammal; contacting the body fluid with a probe which is L2P 14F7, L5P16H4, L1P1C12, L1P12E8 or L1P14D6; and determining the level of unbound bilirubin by measuring binding to the probe and comparing to a standard.

15 **[0027]** Embodiments of the invention are directed to methods for identifying individuals at high risk for disease which includes measuring unbound free fatty acids in the individual by using at least one probe selected from the probes listed in Tables 3-7 and comparing the unbound free fatty acid level in the individual to a level of unbound free fatty acid in a control population.

[0028] Embodiments of the invention are directed to methods of determining a profile of unbound metabolites in body fluids for an individual which includes measuring the concentrations of unbound metabolites with a combination of any of the probes described above. In preferred embodiments, the body fluid is whole blood, blood plasma, blood serum, urine, CSF, saliva, gastric juices, interstitial fluid, synovial fluid or lymph. In preferred embodiments, the unbound metabolite is an unbound free fatty acid.

20 **[0029]** Embodiments of the invention are directed to methods of determining the state of health or disease from an individual's unbound metabolite profile and may include determining an unbound metabolite profile for the individual; and determining that the profile is significantly different than an average profile of patients without the disease. In some preferred embodiments, the unbound metabolite is an unbound fatty acid.

25 **[0030]** Embodiments of the invention are directed to fluorescently labeled proteins based upon SEQ ID NO. 2 which include at least one additional mutation at a position(s) selected from positions 11, 14, 17, 18, 21, 23, 31, 34, 36, 38, 40, 47, 49, 51, 53, 55, 60, 62, 68, 70, 72, 73, 74, 78, 80, 82, 89, 91, 93, 102, 104, 106, 113, 115, 117, 119, and 126.

30 **[0031]** Embodiments of the invention are directed to fluorescently labeled mutants of a parent FABP shown as SEQ ID NO: 4. These fluorescently labeled mutant may have an altered spectral property when associated with an unbound free fatty acid when compared to the parent FABP shown as SEQ ID NO: 4. In preferred embodiments, the mutation includes a substitution.

35 **[0032]** Embodiments of the invention are directed to fluorescently labeled FABPs which include a mutation at position 72 of SEQ ID NO: 2 and at least one additional mutation at a position which is 11, 14, 17, 18, 21, 23, 31, 34, 36, 38, 40, 47, 49, 51, 53, 55, 60, 62, 68, 70, 73, 74, 78, 80, 82, 89, 91, 93, 102, 104, 106, 113, 115, 117, 119, or 126 and which has a value of $\Delta R/\Delta R_{ADIFAB2}$ with an unbound free fatty acid which is more than 0.1.

40 **[0033]** Embodiments of the invention are directed to functional engineered fluorescent proteins whose amino acid sequence includes an amino acid sequence of rat intestinal FABP with at least one amino acid substitution at a position which is 11, 14, 17, 18, 21, 23, 31, 34, 36, 38, 40, 47, 49, 51, 53, 55, 60, 62, 68, 70, 72, 73, 74, 78, 80, 82, 89, 91, 93, 102, 104, 106, 113, 115, 117, 119, or 126.

45 **[0034]** Embodiments of the invention are directed to polynucleotides which include a nucleotide sequence encoding a functional engineered protein which is (a) a protein that includes an amino acid sequence of rat intestinal FABP with at least one amino acid substitution at a position which is 11, 14, 17, 18, 21, 23, 31, 34, 36, 38, 40, 47, 49, 51, 53, 55, 60, 62, 68, 70, 72, 73, 74, 78, 80, 82, 89, 91, 93, 102, 104, 106, 113, 115, 117, 119, or 126 of SEQ ID NO: 4; or (b) a fluorescently labeled FABP with at least one mutation which has a value of $\Delta R/\Delta R_{ADIFAB2}$ with an unbound free fatty acid which is more than 0.1.

50 **[0035]** Embodiments of the invention are directed to expression vectors which include at least one expression control sequence operatively linked to a polynucleotide as described above. Embodiments of the invention are directed to recombinant host cells which include the expression vector described above. In some preferred embodiments, the recombinant host cell may be a prokaryotic cell. In alternate preferred embodiments, the recombinant host cell may be a eukaryotic cell.

55 **[0036]** Embodiments of the invention are directed to iLBPs capable of binding an unbound metabolite and having a value of $\Delta R/\Delta R_{ADIFAB2}$ with an unbound metabolite which is more than 0.1. In preferred embodiments the iLBP is an unbound fatty acid, an unbound bile acid or an unbound retinoic acid.

[0037] Embodiments of the invention are directed to an expression vector which includes a polynucleotide encoding an iLBP operably linked to at least one expression control sequence. Additional embodiments of the invention are directed

to recombinant host cells which include expression vectors encoding an iLBP.

[0038] Embodiments of the invention are directed to methods of selecting probes which are capable of transport into a cell which may include the steps of adding a transport agent to a probe; assaying for transport of the probe into the cell; and selecting for probes that are internalized in the cell. In some preferred embodiments, the probe is specific for an unbound free fatty acid. In some preferred embodiments, the transport agent is a cationic lipid or peptide. In some preferred embodiments, the surface charge of the probe has been altered relative to the template protein.

[0039] Embodiments of the invention are directed to methods of drug discovery which include preparing an array of drugs to be tested, adding a probe, and assaying for binding between the drugs and the probe.

[0040] Embodiments of the invention are directed to methods of monitoring a drug therapy in a diseased patient over a treatment period which may include (a) withdrawing a body fluid from the patient; (b) measuring the binding of an unbound metabolite indicative of the disease to determine a level of the unbound metabolite in the body fluid with a probe; and (c) repeating steps (a) and (b) to measure the level of the unbound metabolite and thereby monitor the drug therapy through the treatment period.

[0041] Embodiments of the invention are directed to methods of measuring an amount of an unbound drug in a mammal which may include withdrawing a body fluid from the mammal; and measuring the binding of the drug or its metabolite to a probe thereby determining the amount of the unbound drug.

[0042] Embodiments of the invention are directed to methods for screening for an efficacy of a drug in a mammal which may include (a) determining a metabolic profile for the mammal; (b) administering a drug to be screened to the mammal; (c) repeating step (a); and (d) comparing the metabolic profile of step (a) with the metabolic profile of step (c) to determine the efficacy of the screened drug.

[0043] Embodiments of the invention are directed to methods of monitoring an effect of a nutrient in a mammal which may include the steps of (a) determining a metabolic profile for the mammal; (b) administering a nutrient to be monitored; (c) repeating step (a); and (d) comparing the metabolic profile of step (a) with the metabolic profile of step (c) to determine the effect of the nutrient.

[0044] Embodiments of the invention are directed to methods of classifying individuals which may include the steps of obtaining a metabolic profile for each individual to be classified; and grouping individuals based upon the metabolic profiles using principle cluster analysis.

[0045] Further aspects, features and advantages of this invention will become apparent from the detailed description of the preferred embodiments that follow.

Brief Description of the Drawings

[0046] Figure 1 shows a flow chart outlining a preferred embodiment of a method of probe production.

[0047] Figure 2 shows the fraction of total FFAu that is arachidonic acid as a function of the ratio of arachidonic acid to BSA.

[0048] Figure 3 shows a binding isotherm for the probe L2P14F7.

[0049] Figure 4 shows a titration of a mixture of 0.5 μM unbound unconjugated bilirubin (UCB) and 1 μM of the probe L2P14F7 with sodium oleate.

[0050] Figure 5 shows the response of L2P14F7 to plasma samples of healthy adult donors in the presence (shaded) and absence (open) of 5 μM unbound unconjugated bilirubin (UCB).

Detailed Description of the Preferred Embodiment

[0051] While the described embodiment represents the preferred embodiment of the present invention, it is to be understood that those skilled in the art can modify the process without departing from the spirit of the invention. Preferred embodiments of the present invention relate to the development of fluorescent molecules ("probes") that can be used to determine the concentration of unbound metabolites. More particularly, the invention relates to 1) high throughput methods to discover such probes, 2) the use of such probes for clinical medicine, drug development and basic science, 3) examples of the development of probes for the determination of the unbound concentration of specific free fatty acids, 4) the use of such probes to provide a profile of unbound metabolites for monitoring the states of health and disease for early diagnosis of human disease and for monitoring the effect of therapeutic intervention on the course of a condition or disease. Other uses include drug screening and monitoring the effect of a nutrient. It is noteworthy that for each probe described, there is cross reactivity between the various categories of metabolites. For example, a probe may bind strongly to retinoic acid but, still have some binding affinity for fatty acids. The probes according to embodiments of the invention find utility in identification and quantification of a wide range of metabolites.

[0052] Probes are proteins that have been 'labeled' through the covalent addition of a fluorescent molecule (fluorophore) to a specific site on the protein and that bind metabolites. Probes have the characteristic that their fluorescence changes in a measurable way when they bind metabolites. Different probes can be generated by mutating the starting

(template) protein and labeling the mutated proteins (mutagens) with a fluorophore. The ability of each such probe to respond to a particular metabolite (or analyte) can then be assessed by measuring the change in fluorescence upon addition of defined concentrations of the unbound metabolite.

5 Generating the library

10 [0053] A library of proteins representing potential probes may be created by any means known in the art. In a preferred embodiment, a protein that is capable of binding one or more unbound metabolites may be used as a template for mutagenesis. In some preferred embodiments, the protein capable of binding one or more unbound metabolites includes serum albumins, acyl CoA binding proteins, phospholipid or glycolipid binding proteins, retinol/retinoic acid binding proteins, bile salt binding proteins, an antibody or a Fatty Acid Binding Protein (FABP). The protein may bind fatty acids, other metabolites or both fatty acids and other metabolites. Besides free fatty acids, possible metabolites include but are not limited to molecules such as drugs, drug metabolites, hormones, prostaglandins, leukotrienes, sphingosine, sphingolipids, phospholipids, glycolipids, cholesterol and cholesterol derivatives and other steroids, lipid-soluble vitamins, bile salts, enzyme cofactors, retinoids such as retinoic acid and retinal, heme and heme metabolites, amino acids, peptides, carbohydrates and multivalent ions.

20 [0054] In more preferred embodiments, an FABP gene, wild-type or mutant, is used as the initial template or starting point for mutagenesis. A collection of mutant FABP clones is generated from the template. In preferred embodiments, mutation involves one or more amino acid substitutions in the binding cavity or the helical cap of the FABP. In a preferred embodiment, a mutant Rat Intestinal Fatty Acid Binding Protein (rI-FABP), which has 131 amino acid residues, was used as the starting point for the mutagenesis.

25 [0055] In more preferred embodiments, sites that alter ligand binding are predominantly ones that are within the binding cavity or on the alpha helices that form the protein "cap" of the FABP. Sites that do not alter ligand binding are predominantly ones that are on the surface of the protein. In some embodiments, a library may be constructed by choosing among the sites that alter ligand binding and then applying random mutagenesis to those sites. Some single site mutants in the stated "cavity" or "cap" may not produce soluble protein or may fail to significantly affect binding. However, the same mutant, when combined with other mutations, may cause significant and favorable changes in ligand binding specificity. Such sites can also be selected experimentally as candidates for multi-site mutagenesis or library construction

30 [0056] Any number of mutagenesis methods may be used to generate a collection or "library" of mutants, said mutagenesis methods include but are not limited to error-prone PCR, site-directed mutagenesis using defined or degenerate oligonucleotides, splicing by overlap extension (SOE), gene shuffling, or the use of mutator host strains. In preferred embodiments, an oligo-directed method of PCR-based mutagenesis was used to generate a collection or "library" of mutants. However, as far as the screening is concerned, it doesn't matter whether the library is composed of known, specific site-directed mutants or an "unknown" random assortment of mutants. Both types of libraries are screened with the same efficiency.

35 [0057] In preferred embodiments, oligos specifying desired mutations prime an enzymatic copying of the vector containing the template gene. The oligo, and therefore the desired mutation(s), is incorporated into the new copy of the gene. The sites mutated in the multi-site mutagenesis libraries of the preferred embodiments are those that were found to alter ligand-binding properties in a library of single point mutants.

40 [0058] Mutant genes are introduced into an organism capable of producing soluble protein from the mutant gene. Any type of organism can be used as long as soluble protein can be harvested from the lysed cells or the cell growth medium. For example, bacteria are used for protein expression in the preferred embodiment, but one skilled in the art could also express the protein in yeast, insect or other eukaryotic cells.

45 Producing the probes

[0059] Protein purification is accomplished by incubating lysate from each clone with a solid support to which the protein is specifically bound with high affinity. There are two ways to make the protein associate with a solid support: a) the protein can be changed to increase its affinity for a solid support or b) the support can be modified to increase its affinity for the protein. The latter can be accomplished, for example, by immobilizing antibodies on the solid support, said antibodies having a high binding-affinity for the protein of interest.

55 [0060] Alternatively the protein may be "tagged" so that it binds to the column material with high affinity. This includes but is not limited to tagging with biotin, Flag-epitope or c-myc epitope or HA-tag, glutathione-S-transferase (GST), maltose binding protein (MBP), a chitin binding domain (CBD), Thioredoxin, β -Galactosidase, VSV-Glycoprotein, calmodulin binding protein, or a metal affinity tag such as a 6X His tag. Preferably, the fusion partner does not change the FABP fatty acid binding properties. The specific association of the affinity tag with the solid support material enables single step purification of the protein of interest from the lysate, which contains thousands of other contaminating proteins and other substances. The affinity tag(s) may be fused at either the NH₂- or COOH- termini or at both termini simultaneously.

In a preferred embodiment, a 6X Histidine tag was fused to either the FABP NH₂- or COOH- termini or at both termini simultaneously without significantly changing the protein's fatty acid binding properties. These fusion proteins can be reversibly immobilized on a solid support for protein purification, delipidation and probe production.

5 **[0061]** Before now, muteins with potentially interesting binding properties were purified with the protein in the mobile, aqueous phase. Protein purification and delipidation required passing the mutein through various types of standard' purification matrices (i.e. size exclusion chromatography, ion exchange chromatography, hydrophobic interaction chromatography (HIC)). The resulting purified and delipidated protein then underwent a buffer exchange process to place it in the fluorophore reaction buffer. After the labeling reaction, the labeled protein was subjected to several HIC chromatography steps to remove unreacted fluorophore. The probe production process, with its intrinsic protein handling losses, and the subsequent assay procedure required the production of milligram quantities (>5 mg) of each mutein. Protein production typically required at least one week per mutein per person and the labeling process required an additional week. Because synthesis of the labeled probe required a significant additional investment of time and money, muteins were only reacted with fluorophore if the binding properties of the unlabeled protein looked promising.

10 **[0062]** In the new process described here, the muteins are affinity purified and left on the affinity purification matrix, essentially making the protein part of the solid phase. Chemical functionalities required for delipidation, labeling, and removal of unreacted label are passed over the protein/solid phase. This is the opposite of the current state of the art process. This new approach enables one person, with minimal automation, to produce approximately 800 labeled muteins in approximately 6 hours. Since we are assaying the probe directly, rather than an unlabeled protein indirectly, the signal is much stronger and very small quantities of probe are required (< 8 μg).

20 **[0063]** By this method a large number of muteins may be constructed, purified, fluorescently labeled and the probes screened for ligand binding in a high throughput format. In a preferred embodiment, the cell growth, cell lysis, protein purification, fluorescent labeling, and probe purification is done in multiwell plates. Preferably, the plates have from 1 to 1536 wells and each well has a volume of between 0.002 ml to 10 ml. By this method, probes may be generated which have different fluorescent responses to different fatty acids or other metabolites as compared to the response of the template. For example, the probe variants may each have different fluorescence spectra and/or different fluorescence intensity at a given emission wavelength when bound to a particular fatty acid as compared to the parent template.

25 **[0064]** In preferred embodiments, the protein variants are labeled with acrylodan while still bound to the solid support. However other fluorescent labels may also be used such as but not limited to dansyl aziridine, 4-[N-[(2-iodoacetoxy)ethyl]-N-methylamino]-7-nitrobenz-2-oxa-1,3-diazole ester (IANBDE), and 4-[N-[(2-iodoacetoxy)ethyl]-N-methylamino-7-nitrobenz-2-oxa-1,3-diazole (IANBDA). Other protein probes that bind unbound metabolites such as unbound FFA and that change their fluorescence upon binding may also be used including, but not limited to, albumin. Albumin with a fluorescent label such as 7-hydroxycoumarin or anthraniloyl changes its fluorescence upon binding FFA (Demant, E, Anal. Biochem. (1999) 267:366-372, Massey, J.B., et al Biophys. J. (1996) 72:1732-1743). Any fluorescent label may be used in the practice of the invention as long as a measurable difference may be detected upon binding of a free fatty acid or other analytes.

35 **[0065]** In a preferred embodiment, the template FABP is recombinant rat intestinal fatty acid binding protein (rl-FABP). Derivatization with acrylodan is performed using known methods substantially as previously described (U.S. Patent No. 5,470,714 & Richieri, G.V, et al., J. Biol. Chem.; (1992) 276: 23495-23501), and the resulting probe (ADIFAB) is commercially available (FFA Sciences LLC, San Diego, CA). A different fluorescence is exhibited by ADIFAB when FFA is bound and the concentration of FFAu can be determined from the change in fluorescence. The wavelength emitted by the fluorescently-labeled FABP depends upon the label and protein used. In an alternate preferred embodiment, the template protein is rl-FABP that has Ala substituted for Leu at position 72 (rl-FABP-L72A) with the resulting probe named ADIFAB2. The binding affinities of ADIFAB2 have been found to be about 10-fold greater than ADIFAB. ADIFAB2 also has an altered spectral response, making it especially useful for measurements of FFAu in blood samples (Apple et al, Clinical Proteomics, (2004) 1:41-44, US Patent Appl 10/670,958). The wavelengths at the maximum intensities emitted by these fluorescently-labeled I-FABP's in the absence of FFA is about 420 to 480 nm. The emission wavelengths at the maximum intensities emitted by these fluorescently-labeled I-FABP's with FFA bound is about 495 to 580 nm. Experiments typically involve measuring the fluorescence response within both emission maxima or at wavelengths for which the effect of interfering molecules such as hemoglobin can be eliminated as described in (US application 10/670958 and PCT/US2004/030521) and the calculation of the ratio 'R' of the two fluorescence intensities. The baseline value for this ratio, measured in the absence of analyte, is designated R₀.

40 **[0066]** Probes produced according to some embodiments of the invention have altered specificity for different FFAu or different unbound metabolites relative to the ADIFAB and ADIFAB2 probes made from the preferred templates-. Altered specificity refers to an alteration in the fluorescence change that occurs when the probe is exposed to different unbound metabolites or different molecular species of FFAu (for example different chain lengths and/or different numbers of double bond and/or different rotational isomers about a given double bond and/or different locations of double bonds.) For example, ADIFAB2 might reveal, when exposed to a particular FFAu1 at a concentration of [FFAu1], a change (ΔR1) in the value of the ratio R relative to R₀. Exposing ADIFAB2 to n such FFAu would reveal a set of responses, {ΔR_i} =

$\Delta R_1, \Delta R_2, \dots, \Delta R_n$. A probe with altered specificities would possess a different set of responses to the same FFAu and concentrations; $\{\Delta R_i\} = \Delta R_1', \Delta R_2', \dots, \Delta R_n'$. With sufficient numbers of different probes possessing different responses it would be possible by measuring the response of each probe to a sample containing mixtures of different FFAu and/or different unbound metabolites, to determine the concentration of each different FFAu and/or different unbound metabolites. Because different states of health and disease might alter the distribution of different FFAu and/or different unbound metabolites in a variety of body fluids including but not limited to whole blood, blood plasma, blood serum, urine, CSF, saliva, gastric juices, interstitial fluid, synoidal fluid or lymph, it can be expected that such a determination would provide valuable information about health status. In addition, such measurements would provide valuable tools for basic research and drug discovery.

Screening the probes

[0067] In some embodiments, aliquots of the probes prepared as described above are placed in multi-well plates, suitable for fluorescence measurements. Defined amounts of ligands are added to each well and a fluorescence signal from the wells containing probe and ligand are compared to wells containing only the probe. The values obtained are compared with those of a 'reference' probe. The ligands may be fatty acids or other unbound metabolites. Preferably, the number of wells in the multiwell plate is between 1 and 1536. Preferably, at least some of the reagents are added to the plates using robotic liquid handling systems. Preferably, the fluorescence signal is measured from each well with a fluorescence plate reader to determine if the signals of each probe are significantly different than those of the parent probe.

[0068] The intensity ratio ("R" value) for a given probe is determined. The ratio is calculated using the following formula:

$$R = F_{\lambda 1} / F_{\lambda 2}$$

wherein, $F_{\lambda 1}$ is the measured fluorescence intensities (intensity of sample with probe present minus intensity of sample without probe present) at wavelength 1 and $F_{\lambda 2}$ is the measured fluorescence intensities (intensity of sample with probe present minus intensity of sample without probe present) at wavelength 2. Then, for a given probe, ΔR , the difference in R value between the measurement in the presence of the analyte and in the absence of the analyte, is calculated as follows:

$$\Delta R = R_{+analyte} - R_0$$

The ΔR value for a given probe is then compared to a reference probe, for example, ADIFAB or ADIFAB2, by $\Delta R / \Delta R_{reference}$. This value is an indication of how dissimilar the new probe (derived by mutation of the template) is to the reference. By this method, probes with new and useful characteristics may be identified. Measurements of fluorescence intensities are obtained using standard techniques.

[0069] Preferably, the fluorescence intensities at two or more wavelengths are measured in each well and the intensity ratios at all combinations of the two or more wavelengths are evaluated to determine if the ratios of each probe are significantly different than those of the reference probe. By this method, probes may be identified that have different specificities in their fluorescence response to different ligands as compared to the reference probe. In preferred embodiments, the ligands are unbound free fatty acids. Other methods for comparing changes in fluorescence with and without analyte can also be used.

[0070] In some embodiments of the invention, the probes are screened for their ability to be transported into a cell. The cell may be procaryotic or eukarotic. Preferably, the cell is a mammalian cell.

[0071] Cell transport may be facilitated by the use of a transport agent, such as a cationic lipid or cationic polymer or peptides. Such cationic lipid transport agents are well known and include, for example, Lipofectamine 2000® (Invitrogen) and peptides include Chariot™ (Active Motif®).

[0072] In preferred embodiments, the transport agent is mixed with the probe and the complex is incubated with cells which have been cultured on a suitable media. After incubation for a suitable period of time, the cells are washed and the ability of the probe to be transported into the cell may be determined by observation under a fluorescence microscope.

[0073] In some embodiments, the surface charge of the probe may be altered relative to the template protein to improve the transfection efficiency.

Using the probes

[0074] A collection of probes with distinct signaling properties can be used to determine the concentrations of different unbound metabolites in a mixture, for example the concentrations of different unbound free fatty acids in a mixture. Thus, an unbound metabolite and/or an unbound free fatty acid profile can be determined for an individual. The most complete profile for fatty acids is the enumeration of the concentrations of each of the unbound free fatty acids in a mixture. This type of profile will require at least n different probes for n fatty acids. Less detailed, but very informative profiles, such as the enumeration of the fractions of different fatty acid classes, can be determined with fewer distinct probes (n probes for n classes). Classes of unbound free fatty acids include saturated, unsaturated, monounsaturated, polyunsaturated, short chain, medium chain, long chain and very long chain. In a preferred embodiment, the concentration of each type of unbound FFA in a mixture is determined. In another preferred embodiment, the fraction of unbound FFA that are unsaturated is determined. In another preferred embodiment, the fraction of FFAu that are monounsaturated is determined. In another preferred embodiment, the fraction of FFAu that are polyunsaturated is determined. In another preferred embodiment, the fraction of FFAu that are saturated is determined. In another preferred embodiment, the fraction of FFAu that are short chain (4-8 Carbon length) is determined. In another preferred embodiment, the fraction of FFAu that are medium chain (10-14 Carbon length) is determined. In another preferred embodiment, the fraction of FFAu that are long chain (16+ Carbon length) is determined. In another preferred embodiment, the fraction of FFAu that are very long chain (20+ Carbon length) is determined. Such determinations are used to generate, for any individual, a profile of unbound FFA that is useful in the diagnosis of disease and the determination of risk factors for disease. Such diseases include but are not limited to cardiac disease, stroke, neurological diseases such as dementia and Alzheimer's disease, diabetes, inflammatory diseases and certain cancers.

[0075] DNA and protein sequences for Fatty Acid Binding Proteins (FABPs) are shown in the sequence listing. SEQ ID NO: 1 shows the cDNA sequence for the wild-type rat intestinal Fatty Acid Binding Protein (rIFABP). The rat fatty acid binding protein is post-translationally modified in the rat, with the modifications including the removal of the N-terminal methionine and the acetylation of the "new" N-terminal residue Ala. Protein sequences are numbered starting with the first residue of the mature protein. Thus, Ala is residue 1 in the corresponding protein shown as SEQ ID NO: 2.

[0076] SEQ ID NO: 3 shows a preferred template rI-FABP-L72A DNA sequence according to the invention. SEQ ID NO: 4 shows the corresponding protein sequence. In this preferred embodiment, the protein has a substitution of alanine at position 72. Other preferred species which are derived from the protein shown as SEQ ID NO: 4 the probes listed in Tables 3,4,5,6,7 and 8.

[0077] In preferred embodiments of the invention, the sample used for the determination of unbound FFA is a fluid sample derived from a human, an animal or a plant. Preferably, the fluid is whole blood, blood plasma, blood serum, urine, CSF, saliva, gastric juices, interstitial fluid or lymph. In some embodiments, unbound metabolites such as unbound FFA are extracted from tissue samples by means known in the art. In other embodiments determination of unbound metabolites such as unbound FFA is performed within the cytoplasm of a cell by microinjecting or otherwise transfecting the probe into the cell. Unbound metabolites include but are not limited to unbound FFA, drugs, drug metabolites, hormones, prostaglandins, leukotrienes, sphingosine, sphingolipids, phospholipids, glycolipids, cholesterol and cholesterol derivatives and other steroids, lipid-soluble vitamins bile salts, enzyme cofactors, retinoids such as retinoic acid and retinal, heme and heme metabolites, amino acids, peptides, carbohydrates and multivalent ions. As discussed above, classes of unbound free fatty acids include saturated, unsaturated, monounsaturated, polyunsaturated, short chain, medium chain and long chain.

[0078] A normal range for a given unbound metabolite is determined from a healthy population and deviations from this normal range may indicate disease. For example, elevated levels of unbound FFA are indicative of cardiac disease. In some embodiments, a metabolic profile is determined for an individual using more than one probe to determine levels of more than one unbound metabolite. Metabolic profiles from a normal, healthy population will be determined. Deviations from a normal metabolic profile are indicative of disease, nutrient deficiency, exposure to toxins or carcinogens and the like.

[0079] In some embodiments, probes produced as described above are used to determine the effect of a drug on a known metabolic profile. The metabolic profile is determined for a test population which may be a normal or non-normal population such as a diseased population. For example, a metabolic profile may be determined for a diseased test population. The diseased test population could then be treated with a drug for a predetermined period of time. The metabolic profile is then redetermined for the test population after drug treatment to observe the effect of the drug on the metabolic profile. In some cases, a change in the metabolic profile may be undesirable, for example, if testing a drug for toxicity and/or unwanted side effects. In other embodiments, a change in metabolic profile may indicate the effectiveness of the drug tested.

[0080] [0067] In some embodiments, a drug therapy in a diseased patient is monitored using one or more probes prepared according to the invention. For example, a body fluid may be withdrawn from the patient. Binding of an unbound metabolite indicative of a disease may be tested using at least one probe produced as described herein. An abnormal level of one or more unbound metabolites is an indicator of a disease state. For example, elevated free fatty acids are

EP 2 385 375 A2

risk factors and indicators of cardiovascular disease; deficiencies in vitamins B6 and folic acid have also been associated with cardiovascular disease and cancer. Levels of the unbound form of these metabolites may be measured or monitored according to the invention using probes generated as described herein.

[0081] In some embodiments, the metabolic profile may be used to determine the effect of specific nutrients on an individual. A metabolic profile may be used to indicate a nutrient deficiency.

[0082] In some embodiments, a metabolic profile may be used to classify individuals into different categories having different susceptibilities to different drugs and/or nutrients. In preferred embodiments, principal component analysis may be used to cluster unbound metabolite profiles into defined groups.

EXAMPLE 1

[0083] Specific point mutations were made at thirty-five sites within the rI-FABP-L72A fatty acid binding pocket, with up to 19 different amino acid residues substituted for the native amino acid at each site. Each mutein contained one substitution. Sites that appeared to produce interesting modifications were used as the starting point for further mutagenesis studies (See Example 2). Mutagenesis was carried out as follows.

[0084] The rI-FABP-L72A open reading frame (ORF) was cloned into a modified pET-11d plasmid/vector (Novagen) at a site that resulted in the fusion of a 6-His affinity tag to the protein COOH-terminus. This template DNA was propagated in *E. coli* strain XL10-Gold (Stratagene). Purification of the template followed standard protocols (Sambrook et al., 1989). The template genes used in other screening examples also encode COOH-terminal 6-His fusions. We have found that the affinity tag can be fused to the NH₂-terminus, the COOH-terminus or both termini of the rI-FABP protein without significantly changing the FFA binding characteristics of the protein.

[0085] Mutant proteins were generated using an oligonucleotide-directed method of PCR-based mutagenesis. Oligonucleotides (oligos) of our design were purchased from QIAGEN. Oligonucleotide primers incorporating the desired mutation(s) were designed with an average length of 33 bases, with 15 bases on each side of the codon for the amino acid to be mutated. The calculated melting temperatures for oligo-template dimers ranged from 60 to 75°C. Mutagenesis reactions for single point mutations utilized single oligos. Reactions to generate multiple possible substitutions at one or multiple sites utilized approximately equimolar amounts of multiple oligos.

[0086] Mutagenic oligos were phosphorylated at their 5' ends with T4 polynucleotide kinase (New England Biolabs, NEB) to allow for ligation during the mutagenesis reaction. Phosphorylation was carried out in a 50 µL reaction mixture containing the following reagents:

1. 300 pmol of oligonucleotide
2. 1 mM ATP
3. 1X T4 polynucleotide kinase reaction buffer (NEB)
 - i. 70 mM Tris-HCl (pH 7.6)
 - ii. 10 mM MgCl₂
 - iii. 5 mM dithiothreitol
4. 10 units of T4 polynucleotide kinase.

The reaction mixture was incubated at 37°C for 30 min. followed by 20 min. incubation at 65°C to deactivate the T4 polynucleotide kinase.

[0087] Mutant, single-stranded, closed-circle copies of the template protein orf in the pET-11d vector were synthesized in 50 µL PCR reactions containing the following reagents:

1. 100 ng of vector containing rIFABP template gene.
2. 10 pmoles 5' of each phosphorylated mutagenic primer.
3. 5 units of thermostable DNA polymerase.
4. 20 units of thermostable ligase.
5. 10 nmoles of each dNTP (dATP, dCTP, dGTP, dTTP).
6. 0.5 X thermostable DNA polymerase buffer
 - a. 10 mM Tris-HCl, pH8.0
 - b. 5 mM KCl
 - c. 5 mM (NH₄)₂SO₄
 - d. 1 mM MgSO₄
 - e. 0.5% Triton X-100

EP 2 385 375 A2

f. 50 $\mu\text{g/ml}$ BSA

7. 0.5 X thermostable ligase buffer

- 5
- a. 10 mM Tris-HCl, pH 7.6
 - b. 12.5 mM potassium acetate
 - c. 5 mM magnesium acetate
 - d. 5 mM DTT
 - e. 0.5 mM NAD
- 10
- f. 0.05% Triton X-100.

[0088] The PCR reactions utilized the following thermal cycler program:

- 15
1. 45°C for 15 minutes (to allow ligase to repair any nicks in DNA template).
 2. 95°C for 2 minutes (activate polymerase and denature template strands).
 3. The following sequence is repeated 30 times:
 - a. 95°C 30 seconds (denaturation)
 - b. 55°C for 45 seconds (anneal mutagenic primers to DNA template)
 - 20 c. 68°C for 14 minutes (DNA synthesis and ligation)
 - d. 45°C for 5 minutes (extended time for ligase to close any gaps).
 4. 72°C for 20 minutes (extend all newly synthesized DNA to full length)
 5. 45°C for 15 minutes (allow ligase to close any gaps)
- 25

[0089] Upon completion of PCR mutagenesis, the reaction mixture was treated with the restriction enzyme DpnI in an attempt to destroy the methylated wild-type template DNA strands. The reaction mixture was subsequently used to transform *E. coli* strain XL10-Gold (Stratagene). For site-specific mutants, clones (colonies) were picked and the presence of the mutation was verified by sequencing or by PCR with oligos designed to hybridize effectively with only the wild-type sequence. For libraries of clones with randomized multiple mutations, all of the XL-10 Gold colonies resulting from transformation with the mutagenesis reaction were utilized. Plasmid DNA was isolated from individual clones (site-specific mutagenesis) or a mixture of clones (multi-mutant libraries) and transformed into the *E. coli* strain BL21-DE3 (Novagen). Synthesis of the mutant protein was induced in 3 ml Luria broth (LB) cultures of single colonies by adding isopropyl-beta-D-thiogalactopyranoside (IPTG) to a final concentration of 0.4 mM. These cultures were grown and harvested in 48 position 5ml rectangular well plates (Innovative Microplates). Induction periods ranged from 2 to 12 hours at 37°C. Cells were harvested by centrifugation and the cell pellets stored in the plates at -80°C.

30

35

[0090] Cell pellets from induced cultures were lysed to release the protein. The 48-well plates were removed from -80 °C storage and the cell pellets thawed by floating the plates in a room temperature water bath. A 400 μl aliquot of lysis buffer was added to each well to disperse and lyse the cells. Lysis buffer has the following composition:

40

1. 50 mM Tris-HCl, pH 8.0
2. 250 mM NaCl
3. 5 mM MgSO_4
4. 5 mM KCl
- 45 5. 0.5ml/ml lysozyme
6. 10 $\mu\text{g/ml}$ Dnase I
7. 10 μM essentially fatty acid free BSA (Sigma, A6003)

[0091] Plates were then subjected to two cycles of freezing and thawing, with freezing occurring in liquid nitrogen and thawing in the room-temperature water bath. Lysates were clarified by centrifugation and the supernatants transferred to 96 position 2.2 ml rectangular well plates (ABgene).

50

Affinity purification and delipidation of the FABP mutants

[0092] Approximately 120 μl of 25% (v/v) Ni-agarose (Sigma His-Select HC, P-6611) suspension was added to each well and the plates sealed with 96-position cap sealing mats (Abgene). Plates were incubated at 4°C for 30 minutes with end-over-end mixing. Beads were pelleted by centrifugation and the supernatants removed by aspiration. The FABP mutants are selectively retained by the Ni-agarose, resulting in a single step purification of the desired proteins.

55

EP 2 385 375 A2

[0093] Each bed of Ni-agarose beads was washed once with Wash Buffer I, which has the following components:

1. 50 mM Tris, pH 8.0
2. 200 mM NaCl
3. 15 μ M essentially fatty acid free bovine serum albumin (BSA)
4. 10 mM imidazole.

[0094] The bovine serum albumin component of the buffer delipidates the FABPs. A failure to fully delipidate the mteins typically results in poor labeling efficiency with the fluorophore. The wash process involved adding 1.5 ml of Wash Buffer I to each bead bed, making sure the beads were well dispersed, sealing the plate with a cap mat, gently shaking the plate, pelleting the Ni-agarose by centrifugation, and removing the supernatant by aspiration.

[0095] Each bed of Ni-agarose beads was then washed three times with 1.5 ml aliquots of Bis-Tris-Propane (BTP) Buffer to remove any residual BSA and to place the protein in the proper buffer for the fluorophore labeling reaction. The BTP Buffer is preheated to 37°C because the subsequent reaction with fluorophore is carried out at 37°C. Bis-Tris-Propane Buffer has the following composition:

1. 10 mM Bis-Tris-Propane, pH 9.3
2. 100 mM NaCl.

[0096] Each wash step with BTP Buffer has the same buffer addition, mixing, centrifugation and aspiration steps as described above for washing with Wash Buffer I. The protein was then ready for reaction with the fluorophore.

Reaction of FABP mteins with the fluorophore

[0097] A 470 μ l aliquot of pre-warmed Bis-Tris-Propane Buffer was added to each bead bed (~ 30 μ l). A 5 μ l aliquot of 20 mM acrylodan stock (20 mM in dimethylformamide) was then added to each sample, the plate sealed with a cap mat, and the plate was shaken to rapidly mix the contents. Plates were gently mixed end-over-end in a 37°C incubator for 60 minutes. Post-incubation plates were centrifuged to pellet the agarose beads and the supernatants discarded through aspiration. Residual unreacted acrylodan was largely removed by washing each bead bed with a 1.5 ml aliquot of Wash Buffer II:

1. 50 mM Tris, pH 8.0
2. 200 mM NaCl
3. 15 μ M essentially fatty acid free BSA.

[0098] The BSA component of Wash Buffer II binds to acrylodan. Residual BSA and acrylodan were removed by washing each bead bed with three 1.5 ml aliquots of Wash Buffer III:

1. 10 mM Tris, pH 8.0
2. 200 mM NaCl

[0099] Labeled mtein probes were released from the Ni-agarose beads by adding 300 μ l of Elution Buffer to each bead bed and gently mixing end-over-end for 20 minutes at room temperature. Elution Buffer had the following composition:

1. 0.85 x HEPES buffer
2. 75 mM EDTA

[0100] The probe concentration for each mtein supernatant in the plate was estimated with the Bradford protein assay (BioRad).

[0101] Mutant probes were screened in 96-well plates by fluorescence response to five fatty acids: arachidonate, linolenate, linoleate, oleate, and palmitate. Each fatty acid was prepared as a complex with BSA by slow addition of 50 mM stocks of fatty acid sodium salts at pH 11 to 600 μ M BSA in HEPES buffer. During the formation of complexes, 15 μ L aliquots were periodically measured with the reference probe, ADIFAB2, to determine the ΔR value upon excitation at 375 nm and fluorescence emission at 550 and 457 nm using a Fluorolog-3 spectrofluorometer (Jobin Yvon) (Richieri et al, Molecular and Cellular Biochemistry (1999), 192:87-94 & Richieri et al, J. Biol. Chem. (1996), 271:31068-31074). Complexes were prepared such that the final ΔR was approximately 0.4 which correspond to [FFAu] ranging from 100 to 1000 nM depending on FFA type. These complexes buffer or clamp the FFAu levels at fixed values and therefore

EP 2 385 375 A2

ensure the accurate comparison of different probes with the same FFAu concentrations. In contrast, addition of FFAu alone (i.e. uncomplexed FFA) introduces considerable uncertainty in comparing different probes because the FFAu level will be affected by binding to the dispensing device, the walls of the multi-well plates and to the probe itself. Thus, the terms "buffer" and "clamp" as used in this particular context herein are taken to mean the ability of a carrier macromolecule to complex with an unbound metabolite so that the unbound metabolite is presented accurately for measurement purposes and is prevented from non-specific binding such as binding to laboratory apparatus.

[0102] Plates were prepared and read in two stages. First, complexes and fatty acid free BSA were diluted to 6 μ M BSA in HEPES and added to the 96-well plate at 300 μ L per well. A MultiProbe II HT (Perkin Elmer) (an automated liquid handling system) was used to facilitate plate preparation for high throughput screening, but any automated or manual pipetting system will suffice. The background fluorescence was then measured at the same wavelengths as used for ADIFAB2 using a Fluorolog-3 spectrofluorometer with an external Micromax 384 fluorescence plate reader (Jobin Yvon). In the second stage, 30 μ L aliquots of the mutant probes were added to multiple wells of the plate, one for each fatty acid and one with fatty acid free BSA only, and the fluorescence intensity at each wavelength was again measured on the plate reader. After subtraction of the background fluorescence, the fluorescence ratio of each well was calculated.

[0103] The fluorescence response was quantitatively compared to ADIFAB2 to search for changes in magnitude and fatty acid profile; for example the response to one fatty acid relative to another. For each probe the ratio differences (ΔR) between wells with each fatty acid compared to a corresponding well with fatty acid free BSA were recorded. The relative response compared to ADIFAB2 was calculated by dividing ΔR for each fatty acid by that for ADIFAB2 ($\Delta R/\Delta RAD2$). Probes that show large ($\Delta R/\Delta RAD2$) and different ($\Delta R/\Delta RAD2$) for different fatty acids were chosen for larger scale production and calibration. The methods described above can be used to screen other fatty acids and / or other unbound metabolites using other plate readers. We have attained equivalent results, for example, using the Gemini EM dedicated fluorescence plate reader (Molecular Devices).

EXAMPLE 2

[0104] Four amino acid positions Y14, L38, L72, and Y 117 of the L72A mutant of rI-FABP shown as SEQ ID NO: 4 were chosen for simultaneous, random mutagenesis. At each position, the native amino acid was potentially replaced with one of 8 other non-native amino acids. This meant that there were nine possible outcomes at each position: G, A, V, I, L, M, F, Y or W. The mutagenesis reaction for this library was carried out essentially as described in EXAMPLE 1. In this case, oligos for changing each of the four positions to the 8 different non-native amino acids (i.e. 32 oligos of equimolar amounts) were added to the mutagenesis reaction simultaneously. E. coli strain XL-10 Gold was transformed using the mutagenesis reaction and all of the resulting colonies pooled for the isolation of plasmid (Sambrook et al., 1989). The isolated plasmid mixture represented the DNA form of the library. An aliquot of library DNA was used to transform the E. coli expression strain BL21-(DE3). Mutant proteins were expressed, purified and labeled as described in Example 1. Over 3000 BL21(DE3) clones were picked and screened from this library. Similarly, a second library containing G, A, V, I, L, M, F, Y and W amino acid substitutions at positions M18, G31, F55, A73 of the L72A mutant of rI-FABP were constructed and approximately 3000 mutant clones screened.

[0105] Screening was conducted by evaluating $\Delta R/\Delta R_{reference}$ as described in paragraphs 0053-0055 and Example 1 for the following fatty acids: palmitate, palmitoleate, stearate, oleate, linoleate, linolenate and arachidonate, where the reference was to ADIFAB2. The screening rate was increased by use of 384 well plates. In this case the total well volume was reduced to 100 μ L and the volume of probe used per well was 10 μ L. Because the identity of each mutant probe was unknown in this example, the probes of interest were organized according to phenotype. Typically, phenotypic clusters could be generated by grouping unknown probes that gave R_0 and $\Delta R/\Delta RAD2$ values within 10 to 20% of each other. Example phenotypes from the 3000 clones screened from the second library are shown in Table 1. The clone ID specifies the second library and well position of each clone. The fluorescence ratio for zero FFAu concentration (R_0) is shown in the second column. The remaining 7 columns are the ratios of the fluorescence response ($R-R_0$) for each probe relative to ADIFAB2 for arachidonate, linolenate, linoleate, oleate, palmitate, palmitoleate and stearate. The phenotypes of these probes reveal, relative to ADIFAB2, one with a large response to POA but smaller ones for OA and SA (L2P21H1), one with a response only for AA and SA (L2P12G9), one with greater response for all 7 FFA (L2P21C1), one with a distinct preference for PA (L2P14F12) and one with little or no response to any of the 7 FFA. It is apparent that such a table with thousands of mutagenesis probe results can be searched for any desired phenotype using an appropriate method of query.

TABLE 1

Example clones from screening of second library

CLONE ID	R ₀	AA	LNA	LA	$\Delta R/\Delta R_{AD2}$	OA	PA	POA	SA
L2P21 H1	0.30	1.02	1.80	1.20	0.55	1.21	2.49	0.39	
L2P12 G9	0.45	0.54	0.01	-0.07	0.07	0.03	-0.01	0.48	
L2P21 C1	0.39	3.27	3.73	4.04	3.20	2.54	3.52	2.02	
L2P14 F12	0.42	0.47	0.72	0.54	0.41	1.09	0.66	0.29	
L2P3 C7	0.10	0.03	0.04	0.04	0.02	0.03	0.05	0.02	

[0106] A strategy was also developed to improve upon "hits" from our primary screening. We have observed that some mutations, when present, create a bias towards distinct phenotypes of mutein probes. While one cannot expect the effects of independently assayed mutations to be simply additive when combined, the signaling or binding characteristics of some mutations are carried through when present in new mutant combinations. This makes it possible to arrive at the desired probe properties through iterations of screening, with the most desirable mutations observed in one library incorporated into the template for the next library. For example, a given library might produce several clones with a desired binding property such as low response to a given FFA or high dynamic range. Sequencing these 'interesting' clones enables one to identify whether a specific mutation is favoring the desired phenotype. If so, the mutation is incorporated into the template for the next round of mutagenesis and the new library is essentially a search for additional phenotypic improvements through synergy with substitutions at other amino acid positions.

[0107] For each probe considered to have a useful phenotype, the sequence is determined, milligram quantities of the probe are prepared and the probe is calibrated. Calibration of a new probe involves quantification of the fluorescence response to varying levels of fatty acids from zero to probe saturation. Spectra of probes were analyzed for true ratio behavior. Binding affinities (e.g. dissociation constant, K_d) and fluorescence parameters were quantified by measuring the fluorescence ratio upon straight titration with fatty acids and titration with fatty acid complexes with known unbound concentrations as determined with ADIFAB (see Richieri et al, Molecular and Cellular Biochemistry (1999), 192:87-94). Using calibration constants, the probe behavior was compared to the initial screen to check for desired properties.

EXAMPLE 3

[0108] Two probes, ADIFAB2 (AD2) and L72V R106Q R126Q (VQQ), were used to determine the concentrations of arachidonic (AA) and palmitic (PA) acids in a prepared mixture of these fatty acids complexed with BSA. Probe VQQ has the unique property that it does not respond to palmitic acid. Four complexes were made as outlined in Example 1: (1) AA:BSA with 50 nM free AA, (2) AA:BSA with 200 nM free AA, (3) PA:BSA with 50 nM free PA, and (4) PA:BSA with 200 nM free PA. These complexes were mixed in ratios ranging from 1:1.5 to 10:1 PA:AA by volume and measured using ADIFAB2 and VQQ. Measurements were done using an SLM 8100 spectrofluorometer (SLM-Aminco) in polystyrene cuvettes. Approximately 15 μ L aliquots of each complex mixture was added to 1.5 mL of HEPES buffer, and about 0.5 μ M of each probe was used. The ratio was measured for each probe and the total unbound FFA concentration and fractional concentrations of arachidonic and palmitic acids were determined using the following equations.

$$FFA_{AA} \left(\frac{R_{m1AA} - R_1}{Q_{1AA} Kd_{1AA}} \right) = R_1 - R_{01}$$

$$FFA_{AA} \left(\frac{R_{m2AA} - R_2}{Q_{2AA} Kd_{2AA}} \right) + FFA_{PA} \left(\frac{R_{m2PA} - R_2}{Q_{2PA} Kd_{2PA}} \right) = R_2 - R_{02}$$

$$FFA_{AA} + FFA_{PA} = FFA_t$$

where the subscripts 1 and 2 refer to probes VQQ and AD2, respectively, and the constants Q, K_d, and R_m were determined via probe calibration as discussed in example 2. R₀ is the ratio in the absence of FFA.

[0109] The solution to the above equations yields FFA_{AA}, FFA_{PA}, and FFA_t. The fractional concentration of AA and

PA are given by $XAA=FFAAA/FFAt$ and $XPA=FFAPA/FFAt$. The results from these measurements are displayed in Figure 2. Complexes with $[FFAu]=50$ nM and 200 nM are shown. For both cases XAA increases linearly with an increase in the volume fraction of AA:BSA complex relative to the PA:BSA complex.

5 EXAMPLE 4

[0110] Using multiple probes the concentrations of different fatty acid classes in a sample were determined. Specifically, blood plasma and serum samples were measured with three different probes with different fatty acid response profiles, each probe generating its own fluorescence ratio. The three probes were ADIFAB2, Y117A L72A, and D74F L72A (each of these represents a mutant protein labeled with acrylodan). The fluorescence ratio with and without sample was measured for each probe, and the relative concentration of saturated (Xs) and unsaturated (Xu) FFA as well as the total unbound FFA (FFAt) concentration in blood plasma and serum samples were determined by simultaneously solving a set of equations (linear in the fraction of each fatty acid class and total fatty acid concentration) based on the calibration of each probe for different fatty acids. For this analysis, saturated fatty acids include stearic and palmitic acids and unsaturated fatty acids include arachidonic, linolenic, linoleic, and oleic acids.

[0111] The set of equations used to determine the FFA concentrations can be expressed in matrix form as shown below.

$$\begin{bmatrix} \frac{R_{ms1} - R_1}{Q_{s1}K_{ds1}} & \frac{R_{mu1} - R_1}{Q_{u1}K_{du1}} & 0 \\ \frac{R_{ms2} - R_2}{Q_{s2}K_{ds2}} & \frac{R_{mu2} - R_2}{Q_{u2}K_{du2}} & 0 \\ \frac{R_{ms3} - R_3}{Q_{s3}K_{ds3}} & \frac{R_{mu3} - R_3}{Q_{u3}K_{du3}} & 0 \\ 1 & 1 & -1 \end{bmatrix} \begin{bmatrix} FFA_s \\ FFA_u \\ FFA_t \end{bmatrix} = \begin{bmatrix} R_1 - R_{01} \\ R_2 - R_{02} \\ R_3 - R_{03} \\ 0 \end{bmatrix}$$

where the subscripts 1,2, and 3 refer to probes ADIFAB2, Y117A L72A, and D74F L72A, respectively, and the subscripts s,u, and t refer to the saturated, unsaturated, and total fatty acids. The values for the constants R_m , K_d , and Q were determined via probe calibration as discussed in example 2, and R_0 is the ratio in the absence of FFA. This matrix was solved to obtain FFAs, FFAu, and FFAt using a least squares method. The fraction of saturated and unsaturated FFA are given by $X_s = FFAs/FFAt$ and $X_u = FFAu/FFAt$.

[0112] Measurements of blood plasma from 12 healthy human donors were conducted with the three probes ADIFAB2, Y117A L72A, and D74F L72A. Measurements were made using a hand-held fluorometer designed for use with these probes (U.S. Patent Application 10/670,958 which is incorporated herein by reference). Approximately 2 μ L of plasma was added to 200 μ L of HEPES buffer in a small glass cuvette, and about 1.5 μ M of each probe was used, Results (Table 2) indicate that the FFAt (the total unbound concentration) for these individuals determined with the three probes is in excellent agreement with the values reported previously for healthy individuals using ADIFAB2 (Apple et al (2004) Clinical Proteomics, 1:41-44). Furthermore the measured Xs values are consistent with values predicted from albumin binding affinities and the distribution of total FFA for healthy individuals (Richieri and Kleinfeld (1995) J. Lipid Res. 36: 229-240). One skilled in the art can extend this method to determine whether states of disease result in different distributions of unbound free fatty acids.

TABLE 2

Healthy Donors		
ID	Xs	FFAt (nM)
N01	0.18	1.9
N02	0.16	1.3
N03	0.22	1.4
N04	0.31	2.7
N05	0.24	1.4
N06	0.13	2.2
N07	0.36	2.2

EP 2 385 375 A2

(continued)

Healthy Donors		
ID	Xs	FFAt (nM)
N08	0.22	0.8
N09	0.23	0.7
N10	0.20	1.0
N11	0.16	1.2
N12	0.20	1.0
average	0.22	1.48
stdev	0.06	0.63

EXAMPLE 5

[0113] Additional probes were produced according to the methods disclosed in Examples 1 and 2. Screening was performed according to Example 2. The results are shown in the attached Tables 3-7. As can be seen from the attached Tables 3-7, it is not necessary to have a mutation at position 72 in order to generate a useful probe. Useful probes are generated by a variety of single and multiple mutations. Generally a value of DR/DR > 0.1 indicates a potentially useful probe. Embodiments of the invention are directed to probes with a value of DR/DR > 0.1, more preferably, > 0.2, yet more preferably, > 0.3, yet more preferably, > 0.4, yet more preferably, > 0.5, yet more preferably, > 0.6, yet more preferably, > 0.7, yet more preferably, > 0.8, yet more preferably, > 0.9, yet more preferably, > 1.0, yet more preferably, > 2.0, yet more preferably, > 3.0.

[0114] Useful probes are also generated by screening for probes in which the value of DR/DR is < 0.1. The clones for these "non-responder" probes may be used to generate non-responder libraries. These non-responder libraries are then screened for their ability to produce probes which bind to metabolites which are not fatty acids. An Example of this type of screen is shown below in Example 6.

TABLE 3: List of responsive clones excluding L72A and WT IFABP

Clone	AvgOfR o	DR/DR AA	DR/DR LNA	DR/DR LA	DR/DR OA	DR/DR RA
102A, 72A	0.24	0.45	0.44	0.35	0.52	0.20
102A1, 72A	0.17	0.50	0.50	0.54	0.52	0.20
102C, 72A	0.24	0.14	0.12	0.12	0.11	0.09
102D, 72A	0.41	0.52	0.61	0.63	0.59	0.28
102E, 72A	0.41	0.56	0.89	0.65	0.60	0.30
102F, 72A	0.25	0.95	0.53	0.73	0.64	0.43
102G, 72A	0.38	0.63	0.38	0.78	0.65	0.36
102H, 72A	0.37	0.52	0.63	0.65	0.66	0.37
102H1, 72A	0.50	1.30	1.22	1.08	0.85	0.56
102I, 72A	0.22	1.46	1.76	1.90	1.93	1.17
102K, 72A	0.39	0.47	0.51	0.55	0.48	0.23
102L, 72A	0.22	1.25	1.41	1.40	1.40	0.97
102M1, 72A	0.16	1.12	1.15	1.17	1.21	1.01
102M2, 72A	0.17	0.78	0.75	0.72	0.72	0.47
102M3, 72A	0.15	0.83	0.75	0.73	0.73	0.52
102N, 72A	0.32	0.64	0.71	0.67	0.69	1.09
102P, 72A	0.34	0.50	0.56	0.54	0.49	0.39
102Q, 72A	0.34	0.62	0.71	0.66	0.60	0.30

EP 2 385 375 A2

(continued)

	Clone	AvgOfR o	DR/DR AA	DR/DR LNA	DR/DR LA	DR/DR OA	DR/DR RA
5	102R, 72A	0.33	0.51	0.57	0.60	0.56	0.25
	102S, 72A	0.24	0.39	0.43	0.45	0.43	0.18
	102T, 72A	0.14	0.21	0.24	0.26	0.26	0.12
	102V, 72A	0.18	0.46	0.51	0.67	0.57	0.35
10	102W1, 72A	0.73	0.30	0.32	0.31	0.30	0.19
	102W2, 72A	0.67	0.47	0.48	0.47	0.46	0.28
	102W3, 72A	0.70	0.44	0.45	0.45	0.40	0.25
	102Y, 72A	0.72	0.72	0.73	0.82	0.86	0.39
15	104D1, 72A	0.65	0.48	0.67	0.71	0.64	0.34
	104F1, 72A	0.35	0.66	0.42	0.47	0.45	0.27
	104F3, 72A	0.34	0.71	0.45	0.50	0.47	0.25
20	104G2, 72A	0.25	0.52	0.95	0.95	0.93	0.70
	104I1, 72A	0.16	0.28	0.30	0.30	0.31	0.23
	104L1, 72A	0.12	0.38	0.42	0.39	0.48	0.31
25	104M1, 72A	0.16	0.67	0.72	0.69	0.73	0.61
	104N1, 72A	0.40	1.14	1.06	0.67	0.71	0.52
	104Q1, 72A	0.43	0.24	0.15	0.13	0.14	0.14
	104R, 72A	0.40	1.18	0.96	0.93	0.88	0.52
30	104R1, 72A	0.47	1.14	1.13	1.22	1.20	1.00
	104S2, 72A	0.24	1.64	1.54	1.71	1.66	1.57
	104T1, 72A	0.22	1.01	1.67	1.16	1.10	0.99
35	104V1, 72A	0.16	0.63	0.73	0.73	0.76	0.63
	104Y1, 72A	0.88	0.36	0.28	0.26	0.24	0.14
	106A1, 72A	0.25	0.39	0.52	0.51	0.60	0.16
	106C2, 72A	0.24	0.17	0.22	0.20	0.22	0.09
40	106D3, 72A	0.30	0.66	0.77	0.80	0.64	0.26
	106F1, 72A	0.31	0.75	0.71	0.78	0.78	0.38
	106G1, 72A	0.25	0.37	0.44	0.48	0.51	0.17
45	106H2, 72A	0.31	0.75	0.73	0.78	0.82	0.33
	106I3, 72A	0.30	0.59	6.71	0.68	0.72	0.29
	106L3, 72A	0.28	0.84	0.84	0.87	0.87	0.43
	106M1, 72A	0.26	0.68	0.62	0.62	0.65	0.28
50	106N1, 72A	0.24	0.38	0.44	0.45	0.50	0.15
	106Q, 72A	0.24	0.37	0.38	0.36	0.39	0.18
	106S2, 72A	0.26	0.32	0.40	0.36	0.48	0.15
55	106T2, 72A	0.26	0.43	0.58	0.47	0.53	0.23
	106V1, 72A	0.30	0.61	0.82	0.82	0.84	0.32
	106W, 72A	0.24	1.11	1.03	1.04	0.99	0.41

EP 2 385 375 A2

(continued)

	Clone	AvgOfR o	DR/DR AA	DR/DR LNA	DR/DR LA	DR/DR OA	DR/DR RA
5	106Y1, 72A	0.17	0.57	0.60	0.61	0.60	0.27
	113M, 72A	0.18	1.33	1.38	1.46	1.42	1.19
	115A1, 72A	0.16	1.17	1.26	1.22	1.20	1.11
	115D1, 72A	0.16	1.17	1.20	1.19	1.21	1.14
10	115E1, 72A	0.22	0.12	0.10	0.15	0.10	0.08
	115F1, 72A	0.23	1.36	1.49	1.46	1.41	0.77
	115G1, 72A	0.17	1.33	1.37	1.36	1.37	1.21
15	115H1, 72A	0.15	0.89	0.70	0.74	0.68	0.51
	115I3, 72A	0.24	0.87	0.80	0.81	0.88	0.84
	115K3, 72A	0.16	1.26	1.32	1.23	1.25	1.18
	115L3, 72A	0.17	1.26	1.29	1.24	1.25	1.15
20	115M2, 72A	0.21	1.45	1.46	1.51	1.52	1.32
	115N2, 72A	0.16	0.92	0.73	0.78	0.71	0.56
	115P1.72A	0.27	-0.17	1.35	1.37	1.26	0.70
25	115R1, 72A	0.40	1.40	1.43	1.45	1.36	0.70
	115S1, 72A	0.39	1.55	1.51	1.51	1.41	0.77
	115T3, 72A	0.21	0.57	0.54	0.45	0.46	0.49
	115V2, 72A	0.28	0.84	0.93	0.87	0.91	0.85
30	115W1, 72A	0.37	1.48	1.40	1.49	1.35	0.81
	115Y1, 72A	0.40	1.42	1.27	1.38	1.23	0.73
	117A, 72A	0.28	1.27	0.62	1.01	0.93	0.32
35	117C, 72A	0.25	-0.17	-0.13	-0.19	-0.24	-0.12
	117D, 72A	0.36	0.41	0.44	0.44	0.35	0.17
	117E, 72A	0.20	0.65	0.64	0.76	0.65	0.40
	117F, 72A	0.19	1.33	1.38	1.36	1.37	1.20
40	117G, 72A	0.36	0.68	0.85	0.92	0.84	0.39
	117H, 72A	0.31	0.90	0.94	1.06	1.01	0.63
	117I, 72A	0.14	0.68	0.68	0.80	0.67	0.41
45	117K, 72A	0.19	0.34	0.37	0.43	0.04	0.22
	117L, 72A	0.11	0.38	0.39	0.43	0.35	0.29
	117M, 72A	0.18	1.27	1.36	1.31	1.32	1.14
	117N, 72A	0.18	1.33	1.37	1.35	1.40	1.19
50	117P, 72A	0.41	0.80	0.83	0.86	0.73	0.38
	117Q, 72A	0.37	1.21	1.24	1.37	1.13	0.63
	117R, 72A	0.41	0.64	0.70	0.70	0.61	0.31
55	117S, 72A	0.36	1.35	1.07	1.42	1.19	0.55
	117T, 72A	0.20	0.79	0.77	0.92	0.81	0.57
	117V, 72A	0.16	0.82	0.81	0.94	0.81	0.49

EP 2 385 375 A2

(continued)

	Clone	AvgOfR o	DR/DR AA	DR/DR LNA	DR/DR LA	DR/DR OA	DR/DR RA
5	117W, 72A	0.29	0.55	0.46	0.45	0.39	0.34
	117Y, 72A	0.18	1.35	1.40	1.44	1.36	1.14
	119A, 72A	0.31	0.70	0.65	0.61	0.63	0.30
	119C, 72A	0.68	1.06	1.00	1.02	0.97	0.35
10	119F, 72A	0.20	0.93	0.93	0.90	0.94	0.69
	119G, 72A	0.25	0.83	0.81	0.77	0.78	0.46
	119H, 72A	0.33	0.71	0.67	0.63	0.59	0.32
15	119I, 72A	0.33	1.01	1.06	1.10	1.08	0.69
	119K, 72A	0.31	0.78	0.78	0.85	0.87	0.58
	119Q, 72A	0.52	0.60	0.62	0.58	0.60	0.35
	119S, 72A	0.31	0.78	0.73	0.46	0.71	0.37
20	119T, 72A	0.25	1.22	1.21	1.22	1.26	0.79
	119V, 72A	0.33	0.99	1.00	1.01	1.02	0.57
	11A1, L72A	0.20	0.60	0.67	0.73	0.64	0.56
25	11C, 72A	0.45	0.52	0.64	0.70	0.70	0.80
	11C2, L72A	0.49	0.51	0.67	0.67	0.66	0.55
	11D1, L72A	0.21	0.82	0.86	0.91	0.92	0.83
	11E2, L72A	0.24	0.54	0.52	0.62	0.55	0.54
30	11F1, L72A	0.32	0.42	6.29	0.28	0.20	0.18
	11G, 72A	0.14	0.63	0.67	0.70	0.62	0.61
	11G1, 72A	0.17	0.81	0.81	0.92	0.85	0.78
35	11G1, L72A	0.14	0.55	0.59	0.70	0.60	0.53
	11H1, 72A	0.21	0.58	0.59	0.55	0.48	0.56
	11H1, L72A	0.18	0.48	0.50	0.47	0.39	0.48
	11I1, L72A	0.38	0.58	0.51	0.55	0.39	1.19
40	11L1, L72A	0.39	0.47	0.35	0.30	0.15	0.27
	11M2, 72A	0.33	0.65	0.59	0.55	0.42	0.57
	11M2, L72A	0.32	0.70	0.65	0.58	0.46	0.54
45	11Q1, 72A	0.26	1.53	1.58	1.72	1.72	1.45
	11Q1, L72A	0.21	1.33	1.43	1.37	1.32	1.19
	11S5, 72A	0.15	0.41	0.39	0.44	0.37	0.47
	11S5, L72A	0.12	0.33	0.37	0.36	0.29	0.35
50	11T1, 72A	0.18	0.51	0.47	0.51	0.41	1.95
	11T1, L72A	0.17	0.49	0.47	0.45	0.35	0.35
	11V2, 72A	0.36	0.93	0.76	0.83	0.55	0.73
55	11W1, 72A	0.26	0.43	0.36	0.34	0.23	0.20
	11W1, L72A	0.29	0.43	0.39	0.40	0.22	0.15
	11Y1, 72A	0.31	0.52	0.31	0.33	0.16	0.30

EP 2 385 375 A2

(continued)

	Clone	AvgOfR o	DR/DR AA	DR/DR LNA	DR/DR LA	DR/DR OA	DR/DR RA
5	11Y1, L72A	0.33	0.49	0.33	0.32	0.16	0.25
	126A, 72A	0.19	1.27	1.36	1.32	1.38	1.22
	126D, 72A	0.38	0.44	0.56	0.59	0.64	0.37
	126E, 72A	0.33	0.25	0.32	0.34	0.30	0.21
10	126F, 72A	0.38	0.52	0.53	0.51	0.43	0.34
	126H, 72A	0.31	0.20	0.46	0.46	0.43	0.32
	126I, 72A	0.30	0.45	0.43	0.43	0.34	0.38
	126L, 72A	0.34	0.66	0.66	0.64	0.55	0.38
15	126M, 72A	0.32	0.32	0.28	0.31	0.24	0.29
	126V, 72A	0.28	0.42	0.42	0.45	0.33	0.34
	14A, 72A	0.44	0.53	0.56	0.56	0.36	0.24
20	14D, 72A	0.44	0.46	0.51	0.53	0.34	0.28
	14E, 72A	0.41	0.51	0.61	0.56	0.41	0.44
	14F, 72A	0.22	0.83	0.88	0.88	0.72	0.60
	14G, 72A	0.44	0.43	0.46	0.42	0.24	0.19
25	14H, 72A	0.35	0.37	0.42	0.45	0.25	0.17
	14I, 72A	0.39	0.57	0.90	0.79	0.57	0.59
	14K, 72A	0.36	1.08	0.92	1.06	0.84	0.47
30	14L, 72A	0.31	0.89	0.93	0.87	0.44	3.07
	14M, 72A	0.33	0.62	0.68	0.68	0.41	0.45
	14N, 72A	0.45	0.42	0.53	0.49	0.35	0.32
	14P, 72A	0.46	0.55	0.64	0.64	0.58	0.30
35	14Q, 72A	0.40	0.50	0.52	0.48	0.29	0.33
	14R, 72A	0.41	0.49	6.51	0.56	0.26	0.26
	14S, 72A	0.46	0.46	0.53	0.53	0.33	0.27
40	14T, 72A	0.46	0.64	1.15	0.76	0.56	0.36
	14V, 72A	0.32	0.76	0.87	0.84	0.51	0.43
	14W, 72A	0.11	0.30	0.31	0.33	0.26	0.23
45	14Y, 72A wt	0.17	1.29	1.29	1.23	2.22	1.07
	17A, 72A	0.28	0.53	0.97	0.56	0.38	0.24
	17C, 72A	0.36	0.15	0.26	0.25	0.31	0.10
	17D, 72A	0.40	0.28	0.34	0.31	0.26	0.16
50	17E, 72A	0.27	0.80	0.88	0.90	0.84	0.53
	17F, 72A	0.19	1.37	1.38	1.35	1.42	1.14
	17G, 72A	0.39	0.48	0.62	0.58	0.52	0.28
	17H, 72A	0.36	0.52	0.50	0.48	0.40	0.22
55	17I, 72A	0.26	0.64	0.54	0.50	0.62	0.28
	17K 72A	0.41	0.28	0.29	0.33	0.31	0.13

EP 2 385 375 A2

(continued)

	Clone	AvgOfR o	DR/DR AA	DR/DR LNA	DR/DR LA	DR/DR OA	DR/DR RA
5	17L, 72A	0.25	0.52	0.45	0.42	0.46	0.28
	17M, 72A	0.30	0.59	0.53	0.49	0.49	0.28
	17N, 72A	0.34	0.47	0.51	0.50	0.49	0.22
	17P, 72A	0.45	0.51	0.63	0.60	0.55	0.24
10	17Q, 72A	0.25	0.62	0.59	0.59	0.55	0.29
	17R, 72A	0.36	0.43	0.48	0.52	0.45	0.22
	17S, 72A	0.35	0.50	0.61	0.56	0.47	0.25
15	17T, 72A	0.32	0.50	0.51	0.51	0.49	0.25
	17V, 72A	0.30	0.64	0.59	0.55	0.56	0.31
	17W, 72A	0.18	1.42	1.61	1.42	1.24	1.07
	17Y, 72A	0.65	0.73	0.81	0.71	0.73	0.50
20	18Q, 72A	0.22	0.09	0.13	0.11	0.08	0.09
	21W, 72A	0.60	3.70	2.40	2.43	3.02	1.45
	23F2, 72A	0.22	0.22	0.17	0.19	0.20	0.12
25	23H1, 72A	0.20	0.16	0.17	0.13	0.11	0.13
	23K1, 72A	0.455	0.13	0.13	0.14	0.13	0.08
	23L3, 72A	0.23	1.17	1.03	1.04	1.06	0.93
	23N1, 72A	0.22	0.12	0.13	0.13	0.12	0.10
30	23P1, 72A	0.32	1.25	1.38	1.36	1.24	0.64
	23R3, 72A	0.20	0.14	0.14	0.14	0.12	0.10
	23T1, 72A	0.16	0.22	0.21	0.33	0.19	0.24
35	23V2, 72A	0.17	1.46	1.35	1.73	1.56	1.48
	23W1, 72A	0.45	0.62	0.96	0.79	0.45	0.49
	23Y1, 72A	0.26	0.49	0.44	0.44	0.41	0.28
40	31C1, 72A	0.30	0.32	0.36	0.36	0.30	0.23
	31D2, 72A	0.31	0.20	0.14	0.16	0.13	6.06
	31E3, 72A	0.35	0.55	0.82	0.74	0.50	0.38
	301F2, 72A	0.43	1.41	1.62	1.76	1.43	1.21
45	31I1, 72A	0.68	0.30	0.41	0.17	-0.21	0.09
	31K2, 72A	0.26	0.85	0.90	0.91	0.97	0.42
	31M2, 72A	0.81	0.52	0.57	0.41	1.08	0.46
	31 N 2, 72A	0.36	0.88	1.06	1.04	0.91	0.50
50	31P1, 72A	0.27	0.25	0.27	0.30	0.22	0.23
	31Q3, 72A	0.38	1.02	1.49	1.47	1.31	1.04
	31R1, 72A	0.18	0.25	0.44	0.40	0.23	0.34
55	31T2, 72A	0.37	0.65	0.91	0.75	0.53	0.41
	31V2, 72A	0.61	0.40	0.78	0.38	0.08	0.21
	31W2, 72A	0.46	0.99	1.03	1.15	0.87	0.62

EP 2 385 375 A2

(continued)

	Clone	AvgOfR o	DR/DR AA	DR/DR LNA	DR/DR LA	DR/DR OA	DR/DR RA
5	31Y1, 72A	0.48	1.78	1.61	1.75	1.55	1.10
	31Y2, 72A	0.69	0.37	0.80	0.36	0.01	0.17
	34A, 72A	0.35	0.58	0.57	0.57	0.49	0.33
	34C, 72A	0.44	0.34	0.33	0.59	10.30	0.18
10	34E, 72A	0.32	0.62	0.57	0.60	0.49	0.48
	34G, 72A	0.51	0.14	0.29	0.33	0.13	0.18
	34H, 72A	0.37	0.65	6.72	0.74	0.52	0.38
	34K, 72A	0.48	0.43	1.33	0.61	0.41	0.26
15	34N, 72A	0.16	1.19	1.18	1.16	1.16	1.11
	34P, 72A	0.42	0.46	0.76	0.66	0.46	0.35
	34Q, 72A	0.37	0.52	0.48	0.56	0.44	0.36
20	34R, 72A	0.52	0.41	0.47	0.61	0.44	0.30
	34S, 72A	0.36	0.58	0.59	0.65	0.58	0.43
	34T, 72A	0.34	0.61	0.67	0.64	0.53	0.40
25	34V, 72A	0.17	1.22	1.21	1.15	1.19	1.11
	34W, 72A	0.24	1.31	1.37	1.34	1.38	0.93
	34Y, 72A	0.18	1.22	1.22	1.24	1.19	1.06
	36A, 72A	0.27	0.53	0.50	0.51	0.46	0.46
30	36C3, 72A	0.38	-0.22	-0.30	-0.36	-0.40	-0.21
	36O1, 72A	0.42	0.20	0.21	0.27	0.20.	0.18
	36E2, 72A	0.31	0.24	0.23	0.25	0.20	0.19
35	36F1, 72A	0.25	0.66	0.66	0.67	0.55	0.52
	36G2, 72A	0.36	1.00	1.16	1.17	0.97	0.55
	36H1, 72A	0.34	0.76	0.86	0.81	0.77	0.40
	36I1, 72A	0.29	1.01	1.13	1.11	0.95	0.80
40	36K, 72A	0.43	0.38	6.42	0.38	0.41	0.16
	36L, 72A wt	0.16	1.25	1.00	1.21	1.25	1.13
	36M, 72A	0.20	1.23	1.08	1.10	1.12.	0.97
45	36N, 72A	0.35	0.47	0.42	0.47	0.38	0.39
	36P, 72A	0.44	0.32	0.36	-7.45	0.14	0.31
	36Q, 72A	0.30	1.20	1.28	1.26	1.12	0.81
	36R, 72A	0.30	1.04	1.17	1.17	1.14	0.70
50	36S, 72A	0.31	0.49	0.10	0.50	0.43	0.142
	36Y, 72A	0.24	0.68	0.68	0.75	0.66	0.60
	38A2, 72A	0.32	1.23	1.30	1.31	1.26	0.68
55	38E1, 72A	0.24	0.57	0.29	0.59	0.59	0.31
	38F1, 72A	0.19	0.91	0.96	0.95	0.97	0.85
	38G1, 72A	0.34	1.03	1.07	1.10	1.03	0.56

EP 2 385 375 A2

(continued)

	Clone	AvgOfR o	DR/DR AA	DR/DR LNA	DR/DR LA	DR/DR OA	DR/DR RA
5	38H1, 72A	0.27	1.24	1.19	1.25	1.16	0.74
	38I3, 72A	0.19	1.18	1.21	1.22	1.21	1.12
	38K1, 72A	0.26	0.83	0.86	0.90	0.76	0.48
	38N1, 72A	0.50	1.08	1.14	1.12	0.97	0.65
10	38O1, 72A	0.26	1.87	1.87	1.90	1.75	1.30
	38S1, 72A	0.32	1.28	1.37	1.37	1.28	0.71
	38T3, 72A	0.30	1.60	1.64	1.58	1.55	1.02
15	38V2, 72A	0.21	1.65	1.67	1.70	1.75	1.50
	38W1, 72A	0.23	1.35	1.34	2.41	1.58	1.55
	38Y1, 72A	0.21	2.08	1.88	1.82	1.72	1.52
	40F2, L72A	0.20	0.89	0.99	0.90	0.90	0.80
20	40M1, L72A	0.20	0.99	1.02	1.09	0.99	0.69
	40V1, L72A	0.21	1.20	1.28	1.24	1.21	0.91
	40Y3, L72A	0.22	0.89	6.49	0.50	0.48	0.29
25	47A1, L72A	0.29	0.54	0.57	0.58	0.59	0.30
	47C3, L72A	0.24	0.32	0.35	0.37	0.35	0.23
	47E3, L72A	0.18	1.25	1.26	1.23	1.25	1.06
	47G1, L72A	0.34	0.51	0.63	0.66	0.59	0.32
30	47H1, L72A	0.22	0.63	0.70	0.74	0.67	0.43
	47I2, L72A	0.19	1.19	1.19	1.22	1.15	0.92
	47L2, L72A	0.22	1.15	1.20	1.21	1.20	0.90
35	47M, 72A	0.23	1.14	1.13	1.18	1.17	0.97
	47M2, L72A	0.18	1.00	0.97	0.99	0.95	0.83
	47P1, L72A	0.36	0.54	0.61	0.59	0.57	0.26
	47Q3, 47Q3, L72A	0.16	0.72	0.73	0.78	0.75	0.46
40	47R3, L72A	0.33	0.56	0.61	0.64	0.62	0.30
	47S1, L72A	0.31	0.61	0.69	0.66	0.64	0.34
	47T1, L72A	0.24	0.68	0.74	0.77	0.74	0.46
45	47V3, L72A	0.19	1.00	1.01	1.04	1.01	0.78
	47W1, L72A	0.17	1.18	1.14	1.18	1.22	1.07
	47Y2, L72A	0.19	1.37	1.40	1.40	1.42	1.17
50	49A1, 72A	0.45	1.72	1.68	1.72	1.60	0.79
	49C1, 72A	0.29	0.13	-0.18	-0.21	-0.20	-0.18
	49D1, 72A	0.23	0.31	0.30	0.32	0.32	0.16
	49F1, 72A	0.39	1.18	1.18	1.14	1.14	0.75
55	49G1, 72A	0.43	1.26	1.25	1.29	1.15	0.64
	49H1, 72A	0.44	1.47	1.54	1.58	1.39	0.75
	49I1, 72A	0.36	1.80	1.82	1.84	1.80	1.16

EP 2 385 375 A2

(continued)

	Clone	AvgOfR o	DR/DR AA	DR/DR LNA	DR/DR LA	DR/DR OA	DR/DR RA
5	49K1, 72A	0.43	1.64	1.68	1.71	1.51	0.80
	49L1, 72A	0.37	1.76	1.77	1.81	1.67	.00
	49M1, 72A	0.35	1.36	1.37	1.37	1.30	0.94
	49N1, 72A	0.35	1.26	1.18	1.10	1.11	0.74
10	49P1, 72A	0.40	1.57	1.53	1.59	1.40	0.76
	49Q, 72A	0.23	0.62	0.55	0.58	0.56	0.43
	49Q1, 72A	0.39	0.92	1.23	1.25	1.20	0.69
	49R1, 72A	0.42	1.68	1.70	1.75	1.56	0.78
15	49S1, 72A	0.40	1.27	1.34	1.29	1.18	0.66
	49T1, 72A	0.28	0.66	0.64	0.67	0.67	0.43
	49W1, 72A	0.31	0.58	0.58	0.58	0.56	0.35
20	49Y1, 72A	0.43	1.39	1.44	1.51	1.34	0.70
	51A1, 72A	0.41	1.38	1.49	1.48	1.28	0.70
	51C3, 72A	0.42	1.44	1.47	1.55	1.35	0.69
	51D1, 72A	0.42	1.34	1.39	1.38	1.28	0.68
25	51F1, 72A	0.43	1.64	1.60	1.70	1.47	0.76
	51G1, 72A	0.41	1.64	1.76	1.71	1.57	0.78
	51H1, 72A	0.35	1.52	1.58	1.64	0.58	0.81
30	51I1, 72A	0.39	1.50	1.62	1.55	1.41	0.72
	51K1, 72A	0.37	1.00	1.02	0.01	1.01	0.56
	51L3, 72A	0.39	1.64	1.66	1.65	1.45	0.76
	51N1, 72A	0.38	1.38	1.39	1.46	1.26	0.73
35	51P3, 72A	0.38	1.42	1.48	1.42	1.21	0.72
	51Q1, 72A	0.40	1.56	1.65	1.63	1.43	0.73
	51R1, 72A	0.40	1.50	1.56	1.56	1.35	0.73
40	51S1, 72A	0.38	1.64	1.66	1.78	1.61	0.80
	51T3, 72A	0.40	1.60	1.60	1.65	1.44	0.71
	51V3, 72A	0.40	1.52	1.53	1.64	1.43	0.73
45	51W2, 72A	0.39	1.69	1.70	1.77	1.55	0.80
	51Y1, 72A	0.38	1.38	1.44	1.50	1.38	6.72
	55A1, 72A	0.18	0.33	0.36	0.34	0.30	0.28
	55D1, 72A	0.18	0.11	0.12	0.12	0.10	0.10
50	55E, 72A	0.25	0.21	0.21	0.21	0.21	0.17
	55G1, 72A	0.20	0.19	0.23	0.22	0.19	0.18
	55H2, 72A	0.18	0.36	0.32	0.38	0.27	0.26
55	55I1, 72A	0.18	1.08	0.89	0.83	0.90	0.77
	55K1, 72A	0.30	0.32	0.35	0.34	0.30	0.27
	55L1, 72A	0.16	0.86	0.72	0.71	0.82	0.63

EP 2 385 375 A2

(continued)

	Clone	AvgOfR o	DR/DR AA	DR/DR LNA	DR/DR LA	DR/DR OA	DR/DR RA
5	55M1, 72A	0.36	1.40	1.42	0.97	1.41	0.84
	55N1, 72A	0.20	0.34	0.30	0.29	0.27	0.22
	55P1, 72A	0.33	1.01	0.96	1.05	0.93	0.54
	55Q1, 72A	0.23	0.60	0.49	0.47	0.54	0.43
10	55R1, 72A	0.24	0.40	0.37	0.41	0.39	0.30
	55S1, 72A	0.20	0.48	0.43	0.42	6.41	0.41
	55T1, 72A	0.17	1.26	1.27	1.25	1.28	1.12
15	55W2, 72A	0.23	0.77	0.82	0.79	0.70	0.63
	55Y3, 72A	0.12	0.47	0.34	6.32	0.33	0.25
	60A, 72A	0.23	0.79	0.94	0.98	0.94	0.74
	60C, 72A	0.17	1.30	1.36	1.33	1.34	1.04
20	60F, 72A	0.25	1.79	1.76	1.68	1.90	1.53
	60G, 72A	0.23	0.29	0.24	0.25	0.24	1.04
	60H, 72A	0.29	0.17	0.18	0.17	0.17	0.12
25	60I, 72A	0.20	1.54	1.63	1.73	1.72	1.52
	60K, 72A	0.41	0.46	0.57	0.62	0.60	0.35
	60L, 72A	0.24	1.08	1.26	1.29	1.27	1.10
	60M, 72A	0.29	0.77	0.93	1.01	0.91	0.76
30	60N, 72A	0.21	1.24	1.59	1.57	1.54	1.30
	60P, 72A	0.40	0.62	0.77	0.81	0.81	0.37
	60Q, 72A	0.27	0.36	0.42	0.41	0.41	0.35
35	60R, 72A	0.27	0.14	0.14	0.12	0.13	0.08
	60S, 72A	0.26	0.56	0.71	0.72	0.67	0.59
	60T, 72A	0.22	1.72	1.73	1.73	1.76	1.49
	60W, 72A	0.18	0.67	0.74	0.84	0.76	0.59
40	62A, 72A	0.27	1.08	1.08	0.96	0.86	0.57
	62C, 72A	0.19	1.30	1.31	1.31	1.29	1.18
	62D, 72A	0.23	1.49	1.58	1.60	1.57	1.39
45	62E, 72A	0.21	1.48	1.52	1.46	1.52	1.40
	62G, 72A	0.22	1.43	1.44	1.44	1.46	1.26
	62H, 72A	0.20	1.42	1.44	1.40	1.40	1.24
	62I, 72A	0.19	1.40	1.38	1.36	1.37	1.27
50	62N, 72A	0.20	1.40	1.40	1.34	1.37	1.29
	62T, 72A	0.24	0.99	0.96	1.02	1.00	0.65
	68A, 72A	0.23	0.23	0.19	0.18	0.19	0.13
55	68C, 72A	0.58	0.18	0.25	0.12	0.29	0.13
	68D, 72A	0.38	1.24	1.23	1.23	1.13	0.52
	68E, 72A	0.36	0.89	0.92	0.96	0.91	0.53

EP 2 385 375 A2

(continued)

	Clone	AvgOfR o	DR/DR AA	DR/DR LNA	DR/DR LA	DR/DR OA	DR/DR RA
5	68G, 72A	0.23	0.24	0.18	0.17	0.21	0.12
	68I, 72A	0.22	0.42	0.36	0.37	0.36	0.35
	68L, 72A	0.21	0.66	6.52	0.53	0.55	0.52
	68M, 72A	0.19	0.52	0.35	0.34	0.35	0.33
10	68N, 72A	0.33	0.67	0.60	0.67	0.63	0.35
	68Q, 72A	0.30	0.47	0.38	0.43	0.45	0.28
	68S, 72A	0.21	0.20	0.14	0.14	0.14	0.10
15	68T, 72A	0.18	0.18	0.12	0.11	0.13	0.10
	68V, 72A	0.20	0.29	0.22	0.23	0.25	0.19
	68Y, 72A	0.17	0.42	0.41	6.36	0.46	0.35
	70C, 72A	0.43	0.23	0.24	0.27	0.24	0.14
20	70M, 72A	0.27	0.34	0.53	0.39	0.42	0.26
	72C	0.30	0.14	0.17	0.25	0.20	0.12
	72D	0.47	0.27	0.41	0.37	0.28	0.24
25	72E	0.57	0.27	0.36	0.38	0.34	0.19
	72F	0.52	0.40	0.59	0.61	0.57	0.46
	72G	0.28	0.62	0.48	0.48	0.52	0.26
	72K	0.40	0.26	0.31	0.26	0.19	0.13
30	72M	0.38	1.31	1.35	1.46	1.49	1.32
	72N	0.31	0.65	0.70	0.77	0.83	0.44
	72Q	0.66	0.77	0.73	0.76	0.78	0.99
35	72R	0.69	0.45	0.49	0.51	0.45	0.26
	72S	0.21	0.65	0.71	0.73	0.62	0.68
	72V	0.09	0.18	0.15	0.21	0.20	0.16
	72Y	0.39	0.35	0.59	0.64	0.56	0.41
40	73E, 72A	0.23	0.15	0.14	0.19	0.14	0.13
	73F, 72A	0.33	1.21	1.86	1.23	0.73	1.13
	73G, 72A	0.22	0.46	0.53	0.56	0.52	0.41
45	73H, 72A	0.11	0.15	0.25	0.18	0.13	0.16
	73K, 72A	0.24	0.30	0.28	0.29	0.28	0.15
	73L, 72A	0.29	0.73	0.34	0.33	0.38	0.25
	73N, 72A	0.21	0.48	0.47	0.43	0.41	0.39
50	73P, 72A	0.15	0.42	0.41	0.30	0.30	0.26
	73Q, 72A	0.27	1.36	1.31	1.39	1.28	1.19
	73R, 72A	0.27	0.40	0.33	6.36	0.27	0.20
55	73S, 72A	0.20	1.01	1.08	1.05	0.96	0.99
	73T, 72A	0.16	0.87	0.77	0.77	0.78	0.62
	73V, 72A	0.30	0.98	0.50	0.40	0.60	0.48

EP 2 385 375 A2

(continued)

5
10
15
20
25
30
35
40
45
50
55

Clone	AvgOfR o	DR/DR AA	DR/DR LNA	DR/DR LA	DR/DR OA	DR/DR RA
73W, 72A	0.39	1.77	1.93	1.89	1.66	1.05
74A, 72A	0.20	1.42	1.42	1.34	1.34	1.27
74C, 72A	0.45	0.83	0.74	0.71	0.56	0.29
74F, 72A	0.25	1.02	1.36	1.19	1.10	1.23
74L, 72A	0.17	0.22	0.40	0.30	0.19	0.36
74N, 72A	0.16	1.62	1.57	1.44	1.52	1.38
74Q, 72A	0.29	0.81	0.86	0.87	0.74	0.43
74T, 72A	0.27	0.76	0.78	0.82	0.70	0.37
78A3, 72A	0.25	0.48	0.50	0.44	0.41	0.25
78C2, 72A	0.35	0.15	0.20	0.20	0.19	0.09
78F1, 72A	0.35	2.04	2.05	2.00	1.83	0.91
78H1, 72A	0.39	1.23	1.26	1.28	1.13	0.57
78I1, 72A	0.56	1.27	1.66	1.11	0.93	0.52
78M1, 72A	0.33	1.39	1.50	1.44	1.44	6.92
78T1, 72A	0.40	1.07	1.20	1.25	1.08	0.54
78W1, 72A	0.32	0.49	0.53	0.57	0.53	0.29
82A, 106A, 72A	0.29	0.11	0.13	0.18	0.13	0.05
82A, 72A	0.41	1.55	1.56	1.67	1.53	0.84
82A1, 72A	0.31	0.73	0.66	0.78	0.80	0.26
82F1, 72A	0.27	0.68	0.76	1.08	0.78	0.41
82I3, 72A	0.24	0.67	0.45	0.52	0.54	0.36
82M1, 72A	0.27	0.97	0.75	0.94	0.92	0.54
82V1, 72A	0.33	0.66	0.76	0.74	0.65	0.48
82Y2, 72A	0.33	0.65	1.57	1.53	1.53	0.88
91A, 72A	0.21	0.86	0.91	0.83	0.85	0.80
93L, 72A	0.41	0.36	0.81	1.03	1.05	0.62
93M, 72A	0.33	0.93	1.19	1.28	1.24	0.75

5
10
15
20
25
30
35
40
45
50
55

TABLE 4

Mutations	Ro	DR/DR AA	DR/DR LNA	DR/DR LA	DR/DR OA	DR/DR PA	DR/DR POA	DR/DR SA	Large Response, Favors AA
21W 72A	0.616	3.829	2.550	2.551	2.808	1.637	2.120	1.946	Favors AA
21 W 78172A	0.664	6.322	4.024	4.381	4.703	2.759	3.284	3.396	
21 W 78F 72A	0.604	4.264	1.694	1.597	1.843	0.851	1.217	1.161	
21W 78A 102V 72A	0.388	4.923	1.628	2.749	3.261	1.721	1.585	3.092	
21 F 781 102F 72A	0.400	4.836	3.006	2.872	3.312	2.383	2.788	2.367	
21F 78V 102V 72A	0.288	4.511	3.775	4.204	4.223	2.756	3.365	3.120	
21Y 78I 102I 72A	0.291	3.536	2.454	2.879	3.424	1.870	2.089	2.774	
21Y, 72A	0.432	2.378	1.881	2.015	1.982	1.094			
38Y 62W 117A 72A	0.554	2.353	1.237	1.848	1.896	0.316	0.272	0.854	
72S 73Q 74A	0.295	2.290	2.077	2.140	1.875	1.896	2.293	1.311	
38Y 117A 72A	0.350	2.216	1.547	1.869	1.976	0.933	0.839	1.201	
38Y, 72A0.213	0.554	2.081	1.884	1.818	1.717	1.518			
14M 18L 31W 73I 117G 72A	0.580	2.032	1.869	2.034	1.712	0.998	1.569	0.487	
38H 62W 106V 117A 72A	0.284	2.007	1.796	1.337	1.239	1.002	1.145	0.947	
14L 31W 117V 72A 14L 31W 117V 72A	0.259	1.972	1.894	2.027	1.580	1.304	1.768	0.742	
38M, 72A	0.261	1.850	1.697	1.805	1.630	1.131			
18G 31F 73L 72A	0.225	1.785	1.235	1.520	1.365	1.025	1.235	1.690	
38M 104S 115A 74F 72A	0.325	1.690	1.615	1.778	1.155	0.498	1.172	0.356	
38Q 62I 106I 117A 72A	0.215	1.656	0.930	1.288	1.167	0.550	0.473	0.663	
62Y, 72A	0.238	1.598	1.395	1.545	1.439	1.037			
38Y 72G 117M	0.204	1.541	1.228	1.233	1.137	0.574			
38A 106V 117A 72A	0.418	1.492	0.541	0.229	0.368	0.033	0.121	0.065	
115W, 72A	0.367	1.483	1.396	1.486	1.352	0.805			

5
10
15
20
25
30
35
40
45
50
55

(continued)

Mutations	Ro	DR/DR AA	DR/DR LNA	DR/DR LA	DR/DR OA	DR/DR PA	DR/DR POA	DR/DR SA
72A 117A	0.273	1.480	0.689	1.193	1.080	0.433		
117S, 72A	0.357	1.467	1.133	1.533	1.258	0.593		
117A, 72A	0.270	1.332	0.631	1.045	0.947	0.331		
14L 18131L 73F 117A 72A	0.255	1.297	0.639	0.707	0.300	0.121	0.235	0.077
38M 72G 117F	0.241	1.280	0.733	0.748	0.686	0.438		
62N 106F 117A 72A	0.224	1.265	0.756	0.985	0.864	0.430	0.341	0.490
49N, 72A	0.345	1.255	1.181	1.099	1.108	0.740		
14L 18T 31 E 73G 117G 72A	0.395	1.236	1.133	1.107	1.096	0.712	1.072	0.413
14L 18L 31L 73G 117V 72A	0.440	1.180	1.139	1.170	0.031	0.377	0.180	0.170
23L, 72A,	0.229	1.174	1.025	1.041	1.057,	0.928		
78Y, 72A	0.314	1.172	0.871	0.908	0.845	0.520		
78I, 72A	0.176	1.138	0.958	0.874	0.923	0.748		
106W, 72A	0.241	1.106	1.030	1.042	0.991	0.407		
78V, 72A	0.255	1.093	0.798	0.865	0.864	0.615		
55I, 72A	0.181	1.079	0.885	0.834	0.901	0.774		
38Q 106W 117A 72A	0.301	1.078	0.795	0.860	0.899	0.444	0.970	0.281
104R, 72A	0.436	1.075	0.904	0.962	0.957	0.791		
119C, 72A	0.679	1.063	1.001	1.022	0.971	0.355		
82F, 72A	0.139	1.029	0.334	0.422	0.403	0.223		
104N, 72A	0.396	1.018.	0.391	0.385	0.408	0.406		
38H, 72A	0.204	0.998	0.864	0.905	0.955	0.624		
73V, 72A	0.300	0.976	0.496	0.396	0.603	0.475		
38I 72G	0.290	0.964	0.701	0.772	0.861	0.419		

5
10
15
20
25
30
35
40
45
50
55

(continued)

Mutations	Ro	DR/DR AA	DR/DR LNA	DR/DR LA	DR/DR OA	DR/DR PA	DR/DR POA	DR/DR SA
14L 18S 31L 73V 117A 72A	0.486	0.951	0.673	0.534	0.020	0.028	-0.003	0.007
21V, 72A	0.269	0.939	0.889	0.871	0.739	0.462		
11V, 72A	0.363	0.932	0.763	0.825	0.552	0.732		
14I 72G 117V 0.312	0.312	0.928	0.547	0.622	0.337	0.085		
14V 18L 73V 117A 72A	0.110	0.926	0.624	0.557	0.307	0.249	0.597	0.105
115N, 72A	0.164	0.918	0.726	0.777	0.711	0.558		
14L 18L 73L 117A 72A	0.372	0.905	0.641	0.657	0.355	0.071	0.410	0.031
115H, 72A	0.155	0.891	0.697	0.741	0.675	0.514		
14Q 18S 731117W 72A	0.487	0.878	0.894	0.784	0.809	0.559	0.834	-0.044
14L 72G 117V	0.280	0.873	0.513	0.548	0.297	0.055		
14L 72G	0.377	0.873	0.886	0.817	0.730	0.334		
73T, 72A	0.157	0.872	0.765	0.768	0.778	0.621		
72G	0.307	0.871	0.590	0.544	0.628	0.307		
104G, 72A	0.162	0.866	0.687	0.665	0.691	0.650		
55L, 72A	0.155	0.863	0.719	0.706	0.822	0.631		
102F, 72A	0.218	0.858	0.588	0.657	0.554	0.369		
14L 72A	0.241	0.838	0.867	0.766	0.446	0.534		
119S, 72A	0.313	0.781	0.734,	0.457	0.714	0.373		
82V, 72A	0.263	0.757	0.456	0.519	0.461	0.345		
73L, 72A	0.294	0.733	0.338	0.325	0.380	0.251		
11M, 72A	0.325	0.697	0.651	0.576	0.463	0.543		
104F, 72A	0.344	0.686	0.436	0.486	0.462	0.263		
68L, 72A	0.207	0.658	0.520	0.530	0.547	0.524		
17I, 72A	0.258	0.640	0.541	0.499	0.624	0.283		

5
10
15
20
25
30
35
40
45
50
55

(continued)

Mutations	Ro	DR/DR AA	DR/DR LNA	DR/DR LA	DR/DR OA	DR/DR PA	DR/DR POA	DR/DR SA
17V, 72A	0.305	0.639	0.586	0.549	0.558	0.308		
34E, 72A	0.317	0.618	0.571	0.604	0.486	0.482		
18L 73V 72A	0.364	0.615	0.126	0.069	0.142	0.083	0.107	0.359
55Q, 72A	0.225	0.600	0.492	0.474	0.536	0.428		
17M, 72A	0.296	0.590	0.532	0.489	0.490	0.281		
55V, 72A	0.169	0.581	0.477	0.432	0.468	0.374		
106M, 72A	0.231	0.554	0.490	0.485	0.510	0.183		
117W, 72A	0.294	0.551	0.461	0.446	0.388	0.339		
119A, 72A	0.304	0.540	0.520	0.450	0.490	0.200		
211, 72A	0.241	0.531	0.412	0.365	0.310	0.162		
17L, 72A	0.251	0.525	0.447	0.420	0.459	0.279		
11Y, 72A	0.309	0.516	0.311	0.330	0.156	0.296		
23Y, 72A	0.265	0.492	0.443	0.442	0.412	0.281		
55Y, 72A	0.124	0.471	0.335	0.324	0.329	0.249		
78A, 72A	0.239	0.433	0.429	0.372	0.350 ;	0.190		
11W, 72A	0.262	0.430	0.357	0.344	0.227	0.199		
104Y, 72A	0.878	0.364	0.278	0.265	0.236	0.140		
38Y 18L 73V 72A	0.386	1.172	0.133	0.034	0.235	0.067	0.023	0.824
18L73V72A	0.455	0.475	-0.028	0.092	0.030	0.010	-0.027	0.427
18L 55L 73I 72A	0.474	0.443	-0.044	-0.129	0.021	0.007	-0.030	0.423
18L 73L 72A	0.283	0.441	0.090	0.019	0.021	-0.004	0.092	0.254
73I 72A	0.276	0.408	0.099	0.039	0.045	0.015	0.117	0.242
18G 31F 73L 72A	0.225	1.785	1.235	1.520	1.365	1.025	1.235	1.690
72F	0.520	0.401	0.592	0.612	0.571	0.456		

AA and SA
specific

AA lowest

5
10
15
20
25
30
35
40
45
50
55

(continued)

Mutations	Ro	DR/DR AA	DR/DR LNA	DR/DR LA	DR/DR OA	DR/DR PA	DR/DR POA	DR/DR SA
72Y	0.386	0.346	0.594	0.637	0.557	0.415		
74F, 72A	0.28	0.44	1.04	0.67	0.51	0.93		
72T 73W 74G	0.205	0.687	1.702	1.348	0.822	1.817	2.770	0.305
38Y 74F 72A	0.191	0.605	1.166	0.926	0.646	1.397	1.514	0.362
73W 74I	0.335	0.757	1.325	1.130	0.912	1.884	2.697	0.423
73W 74T	0.368	1.456	3.286	2.480	1.902	3.883	5.818	0.726
60T 104T 115W 74F 72A	0.136	0.873	2.017	1.609	1.149	1.920	2.511	0.633
72V 73L 74W	0.248	0.500	1.209	1.225	0.648	1.276	1.710	0.348
72H 73P 74L	0.933	4.597	6.352	5.429	3.919	5.260	7.165	1.474
72G 73W 74E	0.576	4.229	5.501	5.045	2.755	3.944	6.069	0.955
72A 73W 74E	0.503	4.093	5.422	4.686	3.277	4.937	6.615	1.289
72T 73W 74S	0.574	4.129	4.826	4.612	4.177	4.155	5.826	1.620
72S 73W 74E	0.520	3.751	4.799	4.079	3.212	4.210	6.109	1.285
72A 73W 74S	0.353	3.211	4.401	3.806	3.155	4.039	4.864	1.095
72S 73W 74N	0.639	3.770	4.220	3.977	3.490	3.333	4.867	1.255
72S 73W 74S	0.597	3.545	4.147	3.787	2.863	3.536	4.656	1.106
73W 72A 74F	0.567	3.378	3.875	3.718	3.255	3.264	5.256	1.485
72T 73W 74E	0.312	2.442	3.818	3.254	2.200	3.842	5.353	0.877
72T 74V	0.249	2.680	3.680	3.630	2.957	3.149	4.074	1.781
72G 73W	0.602	2.260	3.637	2.698	1.106	2.968	4.082	0.294
72T 73V 74V	0.215	3.237	3.618	3.502	3.166	2.987	4.015	1.918
72T 73V 74L	0.386	2.774	3.508	3.165	2.832	2.674	3.642	1.411
72W 73T 74G	0.500	2.808	3.394	3.099	2.514	2.934	4.105	1.040
72S 73L 74A	0.347	3.336	3.322	3.455	3.495	3.293	3.923	2.574

SA and AA lowest

Large Response, Favors
POA, LNA

5
10
15
20
25
30
35
40
45
50
55

(continued)

Mutations	Ro	DR/DR AA	DR/DR LNA	DR/DR LA	DR/DR OA	DR/DR PA	DR/DR POA	DR/DR SA
72T 74I	0.269	2.502	3.169	3.156	2.660	2.476	3.410	1.806
72S 73V 74V	0.356	2.712	3.088	3.085	2.556	2.091	3.322	1.058
72T 73W 74L	0.292	2.721	3.009	2.819	2.340	2.727	3.574	1.217
72T 73Q 74A	0.257	2.392	2.850	3.163	3.136	3.473	3.632	2.318
72T 73V 74S	0.241	2.540	2.579	2.611	2.670	2.629	2.909	2.195
72S 73M 74A	0.358	2.759	2.567	2.470	2.443	2.524	2.854	1.776
72T 73V 74N	0.280	2.484	2.362	2.407	2.491	2.250	2.816	1.942
72S 73P 74I	0.324	2.154	3.091	2.792	2.162	2.210	3.155	1.337
72A 73P 74V	0.377	2.354	2.845	2.735	2.187	2.406	3.613	1.178
18V 31A 73W 72A	0.352	1.761	2.770	2.540	1.738	2.218	3.184	0.722
72A 73W 74V	0.393	1.768	2.752	2.338	1.574	2.525	3.856	0.602
72T 73V 74A	0.242	2.180	2.597	2.435	1.950	2.362	3.011	1.146
72G 73F 74E	0.381	0.910	2.415	1.467	0.585	0.981	2.519	0.239
18I 31I 55M 73V 72A	0.362	1.710	2.408	1.981	1.188	1.883	2.478	0.502
72V 73W 74N	0.207	1.191	2.384	1.726	1.146	2.229	3.507	0.468
18I 31A 73F 72A	0.330	1.314	2.318	1.732	0.950	1.515	2.730	0.404
18I 31A 73F 72A	0.330	1.296	2.203	1.652	0.995	1.372	2.522	0.406
18I 31Y 73V 72A	0.365	1.801	2.176	2.242	1.818	1.615	2.088	1.047
72A 73W 74A	0.268	0.892	2.093	1.466	0.933	1.942	3.016	0.330
72V 73W 74S	0.270	1.424	2.044	1.819	1.477	1.789	2.662	0.574
18V 31A 73F 72A	0.308	1.142	2.036	1.527	0.828	1.510	2.677	0.375
60T 104T 115W 74F 72A	0.136	0.873	2.017	1.609	1.149	1.920	2.511	0.633
14Q 18L 31A 73W 117V 72A	0.334	1.558	1.958	1.942	1.478	1.084	2.008	0.384
18I 31V 73G 72A	0.360	1.348	1.946	1.715	0.968	1.630	2.122	0.543

Favors POA and LNA

5
10
15
20
25
30
35
40
45
50
55

(continued)

Mutations	Ro	DR/DR AA	DR/DR LNA	DR/DR LA	DR/DR OA	DR/DR PA	DR/DR POA	DR/DR SA
18V 31A 55W 73W 72A	0.344	1.130	1.887	1.555	0.913	1.505	2.042	0.392
18I 31I 55M 73I 72A	0.391	1.354	1.803	1.516	0.822	1.546	1.903	0.382
72I 73W 74N	0.229	0.791	1.794	1.194	0.779	2.091	3.236	0.329
73F 72A	0.299	1.051	1.775	1.171	0.630	1.118	2.381	0.399
18I 31L 55L 72A	0.318	1.285	1.736	1.442	0.759	1.523	2.011	0.310
72S 73W 74G	0.321	1.012	1.706	1.375	0.970	1.653	2.422	0.411
73T 72A 74F	0.300	0.939	1.661	1.389	1.161	1.632	2.450	0.519
74T 72A 73F	0.181	0.852	1.635	1.185	0.634	1.150	2.309	0.273 ,
55V 73F 72A	0.328	0.864	1.566	1.223	0.661	1.082	2.264	0.285
74E 72A 73F	0.259	0.703	1.558	1.093	0.575	1.026	2.395	0.251
73P 72A 74F	0.265	1.078	1.518	0.838	0.868	1.278	1.776	0.494
18V 31F 73M 72A	0.314	1.014	1.511	1.296	0.794	1.395	1.538	0.383
74S 72A 73F	0.230	0.893	1.433	1.035	0.630	1.158	2.413	0.337
38I 74F 72A	0.276	0.787	1.395	1.162	0.764	1.343	2.112	0.503
72G 73F 74N	0.513	0.617	1.367	0.454	-0.032	0.456	1.499	-0.043
73W 74I	0.335	0.757	1.325	1.130	0.912	1.884	2.697	0.423
72V 73L 74W	0.248	0.500	1.209	1.225	0.648	1.276	1.710	0.348
18V 31 F 55L 72A	0.303	0.921	1.180	0.996	0.649	1.035	1.353	0.358
18I 31V 55V 73V 72A	0.362	0.632	1.179	0.853	0.448	0.974	1.236	0.233
74Q 72A 73F	0.251	0.465	1.025	0.711	0.390	0.649	1.479	0.177
72E 73V 74A	0.296	0.478	0.784	0.735	0.524	0.736	1.093	0.234
72G 73F 74E	0.381	0.910	2.415	1.467	0.585	0.981	2.519	0.239
18I 31A 73F 72A	0.330	1.296	2.203	1.652	0.995	1.372	2.522	0.406
18I 31L 55L 72A	0.318	1.285	1.736	1.442	0.759	1.523	2.011	0.310
72A 73P 74E	0.199	1.975	1.863	1.741	1.802	1.732	2.087	1.512

5
10
15
20
25
30
35
40
45
50
55

(continued)

Mutations	Ro	DR/DR AA	DR/DR LNA	DR/DR LA	DR/DR OA	DR/DR PA	DR/DR POA	DR/DR SA
18I 31V 55V 73V 72A	0.362	0.632	1.179	0.853	0.448	0.974	1.236	0.233
60T 104T 115W 74F 72A	0.136	0.873	2.017	1.609	1.149	1.920	2.511	0.633
18V 31A 55W 73W 72A	0.344	1.130	1.887	1.555	0.913	1.505	2.042	0.392
18I 31I 55M 73I 72A	0.391	1.354	1.803	1.516	0.822	1.546	1.903	0.382
18I 31I 55M 73V 72A	0.362	1.710	2.408	1.981	1.188	1.883	2.478	0.502
73P 72A 74F	0.265	1.078	1.518	0.838	0.868	1.278	1.776	0.494
18V 31A 73W 72A	0.352	1.761	2.770	2.540	1.738	2.218	3.184	0.722
14Q 18L 31A 73W 117V 72A	0.334	1.558	1.958	1.942	1.478	1.084	2.008	0.384
18I 31M 55M 72A	0.352	1.010	1.358	1.134	0.601	1.099	1.353	0.296
18I 31V 73G 72A	0.360	1.348	1.946	1.715	0.968	1.630	2.122	0.543
18V 31F 55L 72A	0.303	0.921	1.180	0.996	0.649	1.035	1.353	0.358
18V 31F 73M 72A	0.314	1.014	1.511	1.296	0.794	1.395	1.538	0.383
18V 31A 55I 72A	0.345	0.989	1.580	1.334	0.791	1.280	1.563	0.420
72T 73V 74A	0.242	2.180	2.597	2.435	1.950	2.362	3.011	1.146
72S 73P 74I	0.324	2.154	3.091	2.792	2.162	2.210	3.155	1.337
72T 73I 74A	0.293	2.148	1.944	1.795	1.721	1.687	2.320	1.359
72S 74A	0.208	1.648	2.002	2.037	1.575	1.615	2.034	1.114
72S 73V 74A	0.340	2.127	2.330	2.397	2.295	2.601	2.727	1.572
72T 73G 74I	0.311	2.226	2.317	2.577	2.414	2.177	2.771	1.755
72S 73Q 74A	0.295	2.290	2.077	2.140	1.875	1.896	2.293	1.311
18I 31F 72A	0.314	2.043	3.027	2.707	1.761	2.037	2.659	0.950
18I 31Y 72A	0.345	2.205	2.813	2.790	2.096	1.762	2.639	0.994
18I 31 Y 73G 72A	0.298	1.796	2.706	2.559	1.632	1.886	2.637	0.860
72T 74S	0.251	2.035	2.621	2.469	2.252	2.209	2.471	1.779

Favors LNA

5
10
15
20
25
30
35
40
45
50
55

(continued)

Mutations	Ro	DR/DR AA	DR/DR LNA	DR/DR LA	DR/DR OA	DR/DR PA	DR/DR POA	DR/DR SA
14R 18L 31S 73F 117E 72A	0.524	1.241	2.296	1.947	1.146	0.693	1.290	0.378
14R 18L 73L 117D 72A	0.647	1.029	1.790	1.766	0.847	0.294	0.801	0.213
72A 74N	0.162	1.614	1.701	1.681	1.629	1.308	1.536	1.299
14L 18L 31S 73W 117V 72A	0.264	1.458	1.631	1.569	1.208	0.692	1.356	0.329
18V 31A 55I 72A	0.345	0.989	1.580	1.334	0.791	1.280	1.563	0.420
18V 31V 73I 72A	0.329	0.863	1.531	1.151	0.670	1.302	1.334	0.311
18I 31L 73G 72A	0.367	0.981	1.525	1.146	0.595	1.137	1.377	0.267
14L 18L 73W 117S 72A	0.562	1.010	1.499	1.385	0.374	0.259	0.750	0.005
38W 106H 117A 72A	0.414	1.326	1.397	1.248	0.831	0.426	1.098	0.071
18I 31L 72A	0.310	1.054	1.384	1.198	0.719	1.182	1.187	0.305
18I 31M 55M 72A	0.352	1.010	1.358	1.134	0.601	1.099	1.353	0.296
18I 55G 73M 72A	0.303	0.895	1.284	1.127	0.574	1.137	1.201	0.360
18V 31Y 55I 73G 72A	0.383	1.007	1.228	1.220	0.994	0.780	1.106	-0.094
14Q 18S 73I 117W 72A	0.487	0.878	0.894	0.784	0.809	0.559	0.834	-0.044
119M, 72A	0.343	1.087	2.280	1.184	1.191	0.722		
78F, 72A	0.219	2.001	2.033	1.955	1.912	1.416		
14M 72M 117A	0.305	1.649	2.031	1.956	1.054	0.870		
38Q, 72A	0.204	1.976	1.986	1.936	1.842	1.551		
73F, 72A	0.330	1.208	1.861	1.234	0.728	1.128		
38T, 72A	0.297	1.598	1.639	1.577	1.547	1.022		
17W, 72A	0.175	1.421	1.611	1.416	1.241	1.067		
62P, 72A	0.216	1.548	1.581	1.572	1.448	1.247		
31Q, 72A	0.376	1.024	1.494	1.465	1.313	1.039		
38S, 72A	0.311	1.175	1.295	1.286	1.235	0.724		

Favors LNA

5
10
15
20
25
30
35
40
45
50
55

(continued)

Mutations	Ro	DR/DR AA	DR/DR LNA	DR/DR LA	DR/DR OA	DR/DR PA	DR/DR POA	DR/DR SA
14W 72M 117A	0.322	0.945	1.286	1.009	0.706	0.515		
36V, 72A	0.330	1.026	1.082	1.062	0.869	0.713		
74F, 72A	0.28	0.44	1.04	0.67	0.51	0.93		
36I, 72A	0.250	0.812	1.004	0.884	0.773	0.815		
23W, 72A	0.449	0.618	0.956	0.794	0.448	0.492		
17Y, 72A	0.647	0.729	0.806	0.712	0.732	0.500		
31V, 72A	0.613	0.395	0.776	0.384	0.081	0.206		
14M, 72A	0.326	0.619	0.684	0.685	0.412	0.452		
117D, 72A	0.389	0.352	0.407	0.380	0.294	0.142		
31I, 72A	0.680	0.303	0.413	0.168	-0.213	0.091		
104N, 72A	0.396	1.018	0.391	0.385	0.408	0.406		
14L 18L 31Y 73L 117A 72A	0.581	2.987	2.818	2.948	1.908	1.444	2.317	0.762
18I 31F 73V 72A	0.355	2.649	2.738	3.096	2.257	1.893	2.665	1.294
104T 115A 74F 72A	0.287	2.635	2.206	2.231	1.621	0.720	1.661	0.877
18I 31Y 73I 72A	0.340	2.487	2.865	3.031	2.322	1.825	2.620	1.310
18L 73F 117G 72A	0.400	2.445	1.913	2.283	1.908	1.039	1.731	0.663
18V 31Y 73V 72A	0.343	2.400	2.605	2.780	2.349	1.634	2.376	1.330
18V 31I 55L 73V 72A	0.316	2.273	2.433	2.680	2.254	1.253	2.285	1.233
14A 18Y 31W 73G 117V 72A	0.261	0.365	0.940	1.018	0.518	0.421	0.883	0.158
31R, 72A	0.182	0.250	0.437	0.405	0.227	0.342		
31 E, 72A	0.308	0.238	0.522	0.430	0.211	0.223		
74L, 72A	0.172	0.222	0.404	0.305	0.188	0.361		

Favors LNA largest OA
neg
LNA lowest
Favors PUFA,
POA

Favors LNA, LA

5
10
15
20
25
30
35
40
45
50
55

(continued)

Mutations	Ro	DR/DR AA	DR/DR LNA	DR/DR LA	DR/DR OA	DR/DR PA	DR/DR POA	DR/DR SA
31T, 72A	0.389	0.143	0.510	0.215	-0.024	0.145		
18V 31Y 73I 72A	0.359	1.946	2.537	2.619	2.007	1.784	2.528	1.139
78F 102I 72A	0.297	2.093	2.322	2.493	2.506	1.434	2.022	1.877
38W, 72A	0.231	1.350	1.336	2.413	1.583	1.552		
62W, 72A	0.211	2.206	2.120	2.339	2.155	1.450		
18I 31Y 73V 72A	0.365	1.801	2.176	2.242	1.818	1.615	2.088	1.047
14I 18L 31W 73V 117G 72A	0.470	2.037	1.960	2.047	1.756	1.236	1.770	0.606
72S 74A	0.208	1.648	2.002	2.037	1.575	1.615	2.034	1.114
14M 18L 31W 73I 117G 72A	0.580	2.032	1.869	2.034	1.712	0.998	1.569	0.487
14L 31W 117V 72A	0.259	1.972	1.894	2.027	1.580	1.304	1.768	0.742
14Q 18L 31A 73W 117V 72A	0.334	1.558	1.958	1.942	1.478	1.084	2.008	0.384
49I, 72A	0.362	1.796	1.820	1.839	1.804	1.162		
70Q, 72A	0.307	1.546	1.622	1.819	1.604	0.868		
14L 18L 31W 73W 117L 72A	0.201	1.772	1.640	1.782	1.085	0.970	2.059	0.294
38M 104S 115A 74F 72A	0.325	1.690	1.615	1.778	1.155	0.498	1.172	0.356
14R 18L 73L 117D 72A	0.647	1.029	1.790	1.766	0.847	0.294	0.801	0.213
31F, 72A	0.492	1.210	1.647	1.759	1.331	1.438		
23V, 72A	0.167	1.464	1.351	1.731	1.561	1.475		
60I, 72A 11Q, 72A	0.262	1.525	1.582	1.715	1.716	1.450		
104S, 72A	0.242	1.638	1.538	1.715	1.663	1.570		

Favors LA, some LNA about same

5
10
15
20
25
30
35
40
45
50
55

(continued)

Mutations	Ro	DR/DR AA	DR/DR LNA	DR/DR LA	DR/DR OA	DR/DR PA	DR/DR POA	DR/DR SA
73Y, 72A	0.282	1.529	1.603	1.711	1.537	0.982		
72A 74N	0.162	1.614	1.701	1.681	1.629	1.308	1.536	1.299
14I 18V 31W 73I 117V 72A	0.287	1.553	1.495	1.668	0.887	0.652	1.411	0.283
62D, 72A 62D, 72A 0.230	0.230	1.485	1.576	1.598	1.574	1.385		
18L, 72A	0.265	1.490	1.544	1.596	1.551	1.090		
14L 18L 31S 73W 117V 72A	0.264	1.458	1.631	1.569	1.208	0.692	1.356	0.329
21 D, 72A	0.359	1.301	1.478	1.562	1.345	0.707		
117S, 72A	0.357	1.467	1.133	1.533	1.258	0.593		
31Q, 72A	0.376	1.024	1.494	1.465	1.313	1.039		
14L 18L 73W 117S 72A	0.562	1.010	1.499	1.385	0.374	0.259	0.750	-0.005
117Q, 72A	0.368	1.214	1.236	1.374	1.134	0.631		
49M, 72A	0.347	1.363	1.369	1.370	1.296	0.939		
38Q 62I 106I 117A 72A	0.215	1.656	0.930	1.288	1.167	0.550	0.473	0.663
60L, 72A	0.236	1.075	1.260	1.285	1.272	1.095		
18V 31Y 55I 73G 72A	0.383	1.007	1.228	1.220	0.994	0.780	1.106	-0.094
47M, 72A	0.225	1.138	1.135	1.183	1.168	0.966		
31W, 72A	0.462	0.993	1.031	1.147	0.868	0.618		
119L, 72A	0.349	1.021	1.053	1.134	0.778	0.661		
74E72A73F	0.259	0.703	1.558	1.093	0.575	1.026	2.395	0.251
14L 38I 72A	0.267	1.046	1.177	1.090	0.653	0.712		
40M, 72A	0.195	0.993	1.021	1.086	0.990	0.691		
14W 18L 117S 72A	0.228	0.976	0.835	1.063	0.904	0.377	0.811	0.297
36V, 72A	0.330	1.026	1.082	1.062	0.869	0.713		
40V, 72A	0.164	1.013	1.059	1.057	1.002	0.867		

5
10
15
20
25
30
35
40
45
50
55

(continued)

Mutations	Ro	DR/DR AA	DR/DR LNA	DR/DR LA	DR/DR OA	DR/DR PA	DR/DR POA	DR/DR SA
117H, 72A	0.311	0.913	0.924	1.056	1.012	0.659		
117A, 72A	0.270	1.332	0.631	1.045	0.947	0.331		
126K, 72A	0.455	0.625	1.017	1.039	0.631	0.356		
38G, 72A	0.301	0.996	0.992	1.003	0.945	0.447		
60A, 72A	0.227	0.787	0.938	0.977	0.936	0.742		
18K, 72A	0.359	0.800	0.925	0.967	0.803	0.544		
70H, 72A	0.374	0.751	0.886	0.929	0.836	0.567		
36Q, 72A	0.247	0.837	0.880	0.927	0.792	0.777		
117V, 72A	0.153	0.805	0.767	0.924	0.774	0.498		
117T, 72A	0.197	0.791	0.775	0.917	0.813	0.567		
60W, 72A	0.185	0.670	0.739	0.837	0.763	0.595		
14V, 72A	0.317	0.756	0.868	0.836	0.513	0.430		
106F, 72A	0.294	0.754	0.706	0.812	0.815	0.369		
70S, 72A	0.422	0.625	0.703	0.794	0.727	0.416		
141, 72A	0.391	0.572	0.899	0.792	0.572	0.586		
1171, 72A	0.133	0.674	0.666	0.789	0.676	0.408		
117E, 72A	0.196	0.656	0.638	0.753	0.659	0.402		
70W, 72A	0.388	0.349	0.385	0.451	0.381	0.212		
18L 73V 72A	0.364	0.615	0.126	0.069	0.142	0.083	0.107	0.359
73V, 72A	0.300	0.976	0.496	0.396	0.603	0.475		
119S, 72A	0.313	0.781	0.734	0.457	0.714	0.373		
72V 73L 74W	0.248	0.500	1.209	1.225	0.648	1.276	1.710	0.348
14L 18L 31L 73G 117V 72A	0.440	1.180	1.139	1.170	0.031	0.377	0.180	0.170

LA low

LA & PA low

LA, POA high

PUFA high

5
10
15
20
25
30
35
40
45
50
55

(continued)

Mutations	Ro	DR/DR AA	DR/DR LNA	DR/DR LA	DR/DR OA	DR/DR PA	DR/DR POA	DR/DR SA	Favors OA
78F 102I 72A	0.297	2.093	2.322	2.493	2.506	1.434	2.022	1.877	
102I, 72A	0.217	1.461	1.763	1.902	1.929	1.169			
60F, 72A	0.247	1.792	1.762	1.684	1.896	1.526			
91Y, 72A	0.307	1.273	1.626	1.415	1.706	0.870			
38V 62V 117A 72A	0.325	0.984	1.153	1.002	1.668	0.478	0.668	0.495	
91C, 72A	0.334	1.201	1.420	1.371	1.470	0.794			
102L, 72A	0.154	1.103	1.284	1.267	1.366	1.012			
34W, 72A	0.187	1.060	1.130	1.110	1.210	0.920			
119I, 72A	0.303	0.920	0.940	0.960	1.050	0.720			
117H, 72A	0.311	0.913	0.924	1.056	1.012	0.659			
38H, 72A	0.204	0.998	0.864	0.905	0.955	0.624			
18G 31 W 73V 72A	0.232	0.774	0.705	0.855	0.942	0.463	-0.770	0.489	
102Y, 72A	0.719	0.718	0.732	0.818	0.860	0.387			
72N	0.310	0.652	0.702	0.770	0.831	0.441			
55L, 72A	0.155	0.863	0.719	0.706	0.822	0.631			
106F, 72A	0.294	0.754	0.706	0.812	0.815	0.369			
119V, 72A	0.344	0.750	0.710	0.720	0.780	0.480			
93L, 72A	0.312	0.680	0.680	0.670	0.770	0.560			
106H, 72A	0.279	0.636	0.633	0.669	0.732	0.258			
106I, 72A	0.291	0.481	0.624	0.563	0.661	0.223			
106V, 72A	0.261	0.398	0.592	0.574	0.657	0.191			
60K, 72A	0.465	0.461	0.582	0.619	0.626	0.310			
17I, 72A	0.258	0.640	0.541	0.499	0.624	0.283			
106A, 72A	0.249	0.389	0.518	0.515	0.596	0.164			
106N, 72A	0.238	0.384	0.445	0.451	0.496	0.152			

5
10
15
20
25
30
35
40
45
50
55

(continued)

Mutations	Ro	DR/DR AA	DR/DR LNA	DR/DR LA	DR/DR OA	DR/DR PA	DR/DR POA	DR/DR SA
106S, 72A	0.258	0.321	0.403	0.355	0.478	0.149		
106T, 72A	0.228	0.250	0.367	0.246	0.434	0.118		
106L, 72A	0.299	0.383	0.364	0.382	0.431	0.183		
38A 106V 117A 72A	0.418	1.492	0.541	0.229.	0.368	0.033	0.121	0.065
14L 18L 73L 117A 72A	0.372	0.905	0.641	0.657	0.355	0.071	0.410	0.031
38Y 62W 117A 72A	0.554	2.353	1.237	1.848	1.896	0.316	0.272	0.854
38W 106H 117A 72A	0.414	1.326	1.397	1.248	0.831	0.426	1.098	0.071
72G 73F 74N	0.513	0.617	1.367	0.454	-0.032	0.456	1.499	-0.043
14L 18L 31L 73G 117Y 72A	0.440	1.180	1.139	1.170	0.031	0.377	0.180	0.170
31V, 72A	0.613	0.395	0.776	0.384	0.081	0.206		
11Y, 72A	0.309	0.516	0.311	0.330	0.156	0.296		
14I 38I 72V	0.205	0.715	0.926	0.862	0.398	0.844		
14I 72A	0.345	0.825	0.997	0.944	0.478	0.762		
73F, 72A	0.330	1.208	1.861	1.234	0.728	1.128		
11I, 72A	0.382	0.584	0.507	0.546	0.387	1.186		
14L 72A	0.241	0.838	0.867	0.766	0.446	0.534		
14L 38M 72A 117F	0.213	0.861	0.921	0.830	0.458	0.472		
73F 72A	0.299	1.051	1.775	1.171	0.630	1.118	2.381	0.399
72H 73Y 74G	0.205	0.600	0.591	0.472	0.140	0.486	0.986	0.052
31I, 72A	0.680	0.303	0.413	0.168	-0.213	0.091		
18V 31Y 55I 73G 72A	0.383	1.007	1.228	1.220	0.994	0.780	1.106	-0.094
14Q 18S 73I 117W 72A	0.487	0.878	0.894	0.784	0.809	0.559	0.834	-0.044
14L 18L 73W 117S 72A	0.562	1.010	1.499	1.385	0.374	0.259	0.750	-0.005

OA>>PA

Miscellaneous phenotypes

OA neg
SA very low to zero

5
10
15
20
25
30
35
40
45
50
55

(continued)

Mutations	Ro	DR/DR AA	DR/DR LNA	DR/DR LA	DR/DR OA	DR/DR PA	DR/DR POA	DR/DR SA	
38W 106H 117A 72A	0.414	1.326	1.397	1.248	0.831	0.426	1.098	0.071	low SA somewhat low PA
18V 31Y 55I 73G 72A	0.383	1.007	1.228	1.220	0.994	0.780	1.106	-0.094	
72H 73Y 74G	0.205	0.600	0.591	0.472	0.140	0.486	0.986	0.052	
72G 73F 74N	0.513	0.617	1.367	0.454	-0.032	0.456	1.499	-0.043	
73W 74T	0.368	1.456	3.286	2.480	1.902	3.883	5.818	0.726	low OA and SA, AA and POA high Favors POA and PA
72T 73Q 74S	0.283	2.166	2.419	2.713	2.676	2.646	3.110	1.792	
72S 73V 74A	0.340	2.127	2.330	2.397	2.295	2.601	2.727	1.572	
72G 74F	0.467	1.669	1.970	2.116	1.490	2.304	2.996	0.669	
72I 73W 74N	0.229	0.791	1.794	1.194	0.779	2.091	3.236	0.329	
73W 74I	0.335	0.757	1.325	1.130	0.912	1.884	2.697	0.423	
72T 73W 74G	0.205	0.687	1.702	1.348	0.822	1.817	2.770	0.305	
73N 72A 74F	0.448	0.870	1.299	0.976	0.775	1.468	2.256	0.271	
38Y 74F 72A	0.191	0.605	1.166	0.926	0.646	1.397	1.514	0.362	
72V 73L 74W	0.248	0.500	1.209	1.225	0.648	1.276	1.710	0.348	
11I, 72A	0.382	0.584	0.507	0.546	0.387	1.186			
18I31 L 73L 72A	0.380	0.626	0.857	0.682	0.549	1.075	0.781	0.390	
72Q	0.665	0.770	0.735	0.762	0.777	0.989			
14L 18L 73L 117A 72A	0.372	0.905	0.641	0.657	0.355	0.071	0.410	0.031	
38A 106V 117A 72A	0.418	1.492	0.541	0.229	0.368	0.033	0.121	0.065	
14I 72G 117V	0.312	0.928	0.547	0.622	0.337	0.085			
14L 72G 117V	0.280	0.873	0.513	0.548	0.297	0.055,			
14L 18S 31L 73V 117A 72A	0.486	0.951	0.673	0.534	0.020	0.028	-0.003	0.007	
106D, 72A	0.240	0.502	0.591	0.584	0.423	0.147			

PA & SA very low
AA highest
AA highest
AA highest
AA highest

5
10
15
20
25
30
35
40
45
50
55

(continued)

Mutations	Ro	DR/DR AA	DR/DR LNA	DR/DR LA	DR/DR OA	DR/DR PA	DR/DR POA	DR/DR SA
31I, 72A	0.680	0.303	0.413	0.168	-0.213	0.091		
55Y, 72A	0.124	0.471	0.335	0.324	0.329	0.249		
14L 72G 117I	0.246	0.787	0.812	0.764	0.395	0.231		
82F, 72A	0.139	1.029	0.334	0.422	0.403	0.223		
106I, 72A	0.291	0.481	0.624	0.563	0.661	0.223		
70W, 72A	0.388	0.349	0.385	0.451	0.381	0.212		
119A, 72A	0.304	0.540	0.520	0.450	0.490	0.200		
11W, 72A	0.262	0.430	0.357	0.344	0.227	0.199		
106V, 72A	0.261	0.398	0.592	0.574	0.657	0.191		
72A_	0.239	0.433	0.429	0.372	0.350	0.190		
78A,	0.231	0.554	0.490	0.485	0.510	0.183		
106M, 72A 106L, 72A	0.299	0.383	0.364	0.382	0.431	0.183		
106A, 72A	0.249	0.389	0.518	0.515	0.596	0.164		
21I, 72A	0.241	0.531	0.412	0.365	0.310	0.162		
49D, 72A	0.231	0.308	0.296	0.324	0.316	0.161		
106N, 72A	0.238	0.384	0.445	0.451	0.496	0.152		
106S, 72A	0.258	0.321	0.403	0.355	0.478	0.149		
117D, 72A	0.389	0.352	0.407	0.380	0.294	0.142		
104Y, 72A	0.878	0.364	0.278	0.265	0.236	0.140		
14L 18I 31L 73F 117A 72A	0.255	1.297	0.639	0.707	0.300	0.121	0.235	0.077
106T, 72A	0.228	0.250	0.367	0.246	0.434	0.118		
18L 73V 72A	0.364	0.615	0.126	0.069	0.142	0.083	0.107	0.359
73W 74T	0.368	1.456	3.286	2.480	1.902	3.883	5.818	0.726
72A 73W 74V	0.393	1.768	2.752	2.338	1.574	2.525	3.856	0.602
72A 73P 74V	0.377	2.354	2.845	2.735	2.187	2.406	3.613	1.178

PA & SA low

Favors POA

5
10
15
20
25
30
35
40
45
50
55

(continued)

Mutations	Ro	DR/DR AA	DR/DR LNA	DR/DR LA	DR/DR OA	DR/DR PA	DR/DR POA	DR/DR SA
72V 73W 74N	0.207	1.191	2.384	1.726	1.146	2.229	3.507	0.468
721 73W 74N	0.229	0.791	1.794	1.194	0.779	2.091	3.236	0.329
72T 73Q 74S	0.283	2.166	2.419	2.713	2.676	2.646	3.110	1.792
72A 73W 74A	0.268	0.892	2.093	1.466	0.933	1.942	3.016	0.330
72G 74F	0.467	1.669	1.970	2.116	1.490	2.304,	2.996	0.669
72T 73W 74G	0.205	0.687	1.702	1.348	0.822	1.817	2.770	0.305
181 31A 73F 72A	0.330	1.314	2.318	1.732	0.950	1.515	2.730	0.404
73W 74I	0.335	0.757	1.325	1.130	0.912	1.884	2.697	0.423
18V 31A 73F 72A	0.308	1.142	2.036	1.527	0.828	1.510	2.677	0.375
72V73W74S	0.270	1.424	2.044	1.819	1.477	1.789	2.662	0.574
73T 72A 74F	0.300	0.939	1.661	1.389	1.161	1.632	2.450	0.519
72S 73W 74G	0.321	1.012	1.706	1.375	0.970	1.653	2.422	0.411
74S 72A 73F	0.230	0.893	1.433	1.035	0.630	1.158	2.413	0.337
74E 72A 73F	0.259	0.703	1.558	1.093	0.575	1.026	2.395	0.251
73F 72A	0.299	1.051	1.775	1.171	0.630	1,118	2.381	0.399
74T 72A 73F	0.181	0.852	1.635	1.185	0.634	1,150	2.309	0.273
55V 73F 72A	0.328	0.864	1.566	1.223	0.661	1,082	2.264	0.285.
73N 72A 74F	0.448	0.870	1.299	0.976	0.775	1.468	2.256	0.271
38I 74F 72A	0.276	0.787	1.395	1.162	0.764	1.343	2.112	0.503
14L 18L 31W 73W 117L 72A	0.201	1.772	1.640	1.782	1.085	0.970	2.059	0.294
72V 73L 74W	0.248	0.500	1.209	1.225	0.648	1.276	1.710	0.348
38Y 74F 72A	0.191	0.605	1.166	0.926	0.646	1.397	1.514	0.362
74Q 72A 73F	0.251	0.465	1.025	0.711	0.390	0.649	1.479	0.177
72E 73V 74A	0.296	0.478	0.784	0.735	0.524	0.736	1.093	0.234

5
10
15
20
25
30
35
40
45
50
55

(continued)

Mutations	Ro	DR/DR AA	DR/DR LNA	DR/DR LA	DR/DR OA	DR/DR PA	DR/DR POA	DR/DR SA
72H 73Y 74G	0.205	0.600	0.591	0.472	0.140	0.486	0.986	0.052
72G 73F 74N	0.513	0.617	1.367	0.454	-0.032	0.456	1.499	-0.043
14L 18L 73W 117S 72A	0.562	1.010	1.499	1,385	0.374	0.259	0.750	-0.005
14Q 18S 73I 117W 72A	0.487	0.878	0.894	0.784	0.809	0.559	0.834	-0.044
14L 18L 31L 73G 117V								
72A	0.440	1.180	1.139	1.170	0.031	0.377	0.180	0,170
38A 106V 117A 72A	0.418	1.492	0.541	0.229	0.368	0.033	0.121	0.065
14L 18S 31L 73V 117A								
72A	0.486	0.951	0.673	0.534	0.020	0.028	-0,003	0.007
38Y 117A 72A	0.350	2.216	1.547	1.869	1.976	0.933	0.839	1.201
62N 106F 117A 72A	0.224	1.265	0.756	0.985	0.864	0.430	0.341	0.490
38Y 62W 117A 72A	0.554	2.353	1.237	1.848	1.896	0.316	0.272	0.854
38Q 62I 106I 117A 72A	0.215	1.656	0.930	1.288	1.167	0.550	0.473	0.663

PA & SA lowest POA and LNA highest
SA ~ zero, LNA, LA specific
SA ~ zero
OA lowest, PUFA highest
PA lowest, AA highest by 3 fold
POA lowest

EP 2 385 375 A2

TABLE 5

DR/DRAD2

	Clone	Ro	AA	LNA	LA	OA	PA
5	L72A	0.17	1.12	1.16	1.14	1.15	1.02
	L72G	0.28	0.62	0.48	0.48	0.52	0.26
	L72M	0.38	1.31	1.35	1.46	1.49	1.32
	A73F, L72A	0.33	1.21	1.86	1.23	0.73	1.13
10	A731, L72A	0.27	0.38	0.03	-0.04	-0.04	-0.04
	D74F, L72A	0.25	0.44	1.04	0.67	0.51	0.93
	L78F, L72A	0.35	2.04	2.05	2	1.83	0.91
	W82F, L72A	0.27	0.68	0.76	1.08	0.78	0.41
15	R106W, L72A	0.24	1.11	1.03	1.04	0.99	0.41
	Y117A, L72A	0.28	1.27	0.62	1.01	0.93	0.32
20	Y117S, L72A	0.36	1.35	1.07	1.42	1.19	0.55

TABLE 6

$\Delta R/DRA\Delta 2$

Mutations

	ID	Ro	AA	LNA	LA	OA	PA	Y14	L38	L72	Y117
25	L1 P8 H2	0.69	-1.3	-1.3	-1.5	-1.7	-0.6	M	M	W	wt
	L1P7 H4	0.62	-1.0	-1.1	-1.3	-1.4	-0.6	I	M	W	wt
	L1 P1 C3	0.60	-0.9	-1.0	-1.1	-1.3	-0.4	M	wt	W	wt
30	L1P17 A1	0.56	-0.8	-0.9	-1.0	-1.2	-0.4	I	wt	W	wt
	L1P12	0.59	-0.5	-0.7	-0.7	-1.0	-0.1	L	wt	W	wt
	E11										
	L1P12	0.28	0.9	0.5	0.5	0.3	0.1	L	wt	G	V
	F12										
35	L1 P2 F7	0.32	0.9	0.5	0.6	0.3	0.1	I	wt	G	V
	L1P7 B11	0.21	0.7	0.9	0.9	0.4	0.8	I	I	V	wt
	L1P12	0.35	0.8	1.0	0.9	0.5	0.8	I	wt	wt	wt
	G10										
40	L1 P3 D6	0.24	0.9	0.9	0.8	0.5	0.5	L	wt	wt	wt
	L1P1 F7	0.22	0.9	1.0	0.9	0.5	0.5	L	M	wt	F
	L1P14 A9	0.25	0.8	0.8	0.8	0.4	0.2	L	wt	G	I
	L1P11	0.27	1.0	1.2	1.1	0.7	0.7	L	I	wt	wt
	F12										
45	L1P17 A8	0.24	1.3	0.7	0.8	0.7	0.4	wt	M	G	F
	L1P9 G10	0.29	1.0	0.7	0.8	0.9	0.4	wt	I	G	wt
	L1P16	0.34	0.9	1.3	1.1	0.7	0.8	W	wt	M	A
	G10										
50	L1P5 A10	0.28	1.5	0.7	1.2	1.1	0.4	wt	wt	wt	A
	L1 P8 D4	0.31	1.6	2.0	2.0	1.1	0.9	M	wt	M	A

TABLE 7

$\Delta R/DRA\Delta 2$	Sequence											
ID	Ro	AA	LNA	LA	OA	PA	POA	SA	M18	G31	F55	A73
L2P17H10	0.23	1.8	1.2	1.5	1.4	1.0	1.2	1.7	G	F	WT	L

EP 2 385 375 A2

(continued)

$\Delta R/DRA\Delta 2$		Sequence											
ID	Ro	AA	LNA	LA	OA	PA	POA	SA	M18	G31	F55	A73	
5	L2P22G6	0.30	1.8	2.7	2.6	1.6	1.9	2.6	0.9	I	Y	WT	G
	L2P11B4	0.35	1.8	2.8	2.6	1.9	2.2	3.1	0.7	V	A	WT	W
	L2P2E11	0.31	1.9	2.8	2.5	1.6	2.0	2.6	0.8	I	F	WT	WT
	L2P4C5	0.35	2.2	2.8	2.8	2.1	1.8	2.6	1.0	I	Y	WT	WT
	L2P1 E6	0.34	0.4	0.1	0.1	0.1	0.0	0.1	0.2	L	WT	WT	L
10	L2P8F11	0.28	0.4	0.1	0.0	0.0	0.0	0.1	0.3	WT	WT	WT	I
	L2P12G9	0.46	0.5	0.0	-0.1	0.0	0.0	0.0	0.4	L	WT	WT	V
	L2P9E12	0.38	0.6	0.9	0.7	0.6	1.1	0.8	0.4	L	WT	L	I
	L2P22H10	0.30	0.9	1.3	1.1	0.6	1.1	1.2	0.4	I	WT	G	M
15	L2P8B8	0.31	1.1	1.8	1.2	0.6	1.1	2.4	0.4	WT	WT	WT	F
	L2P16A3	0.37	1.0	1.5	1.1	0.6	1.1	1.4	0.3	I	L	WT	G
	L2P7F4	0.32	0.8	1.5	1.1	0.6	1.3	1.3	0.3	V	V	WT	I
	L2P21G3	0.36	1.0	1.4	1.1	0.6	1.1	1.4	0.3	I	M	M	WT
	L2P23G7	0.30	0.9	1.2	1.0	0.6	1.0	1.4	0.4	V	F	L	WT
20	L2P22E6	0.35	1.0	1.6	1.3	0.8	1.3	1.6	0.4	V	A	I	W
	L2P18H1 2	0.36	1.3	1.9	1.7	1.0	1.6	2.1	0.5	I	V	WT	G
	L2P8A5	0.35	1.1	1.9	1.6	0.9	1.5	2.0	0.4	V	A	W	W
	L2P21C1	0.36	2.8	3.1	3.4	2.7	2.0	2.9	1.6	I	Y	WT	V
25	L2P23A4	0.40	2.8	2.6	3.1	2.3	1.9	2.8	1.2	V	I	L	V
	L2P12C5	0.39	1.3	1.7	1.5	0.8	1.5	1.9	0.4	I	I	M	I
	L2P8A6	0.36	0.6	1.2	0.8	0.4	1.0	1.3	0.2	I	V	V	V

EXAMPLE 6

30 [0115] A probe for unbound unconjugated bilirubin (UCBu) was developed and used to measure concentrations of UCBu in plasma spiked with a defined quantity of unconjugated bilirubin (UCB). Using 384-well plates, 335 mutant probes that were insensitive to FFA were screened for their response to UCB:BSA complexes at UCB:BSA ratios of 1:1, and 1:2 in aqueous buffer. All probes were prepared from rI-FABP-L72A with 1 to 5 mutations. Screening was conducted by comparing the fractional change in fluorescence intensity ($\Delta I/I_0$, where ΔI is the difference in probe intensity in the presence and absence of UCB and I_0 is the intensity in the absence of UCB) for the probes with that for ADIFAB2. This value was calculated for two emission wavelengths: 440 and 500 nm. Several probes were identified that had significantly improved responses to UCBu as compared to the template, ADIFAB2 (Table 8). The emitted fluorescence of these probes is quenched by binding of UCB.

TABLE 8

PROBE ID	$\Delta I/I_0$				Kd (nM) at 22°C	Mutations	
	1:2 UCB:BSA 440 nm 500 nm		1:1 UCB:BSA 440 nm 500 nm				
45	ADIFAB2	-0.19	-0.16	-0.40	-0.34	--	--
	L1P1 B4	-0.36	-0.35	-0.66	-0.64	590	14I 72W 117W
	L1P1C12	-0.86	-0.79	-0.92	-0.86	37	381 72W 117W
	L1P12 E8	-0.45	-0.39	-0.79	-0.70	112	14L 38A 72G 117F 114E
50	L1P14 D6	-0.37	-0.33	-0.69	-0.64	230	14M 72V 117W
	L1P5 H9	-0.34	-0.34	-0.58	-0.63	490	14M 721 117W
	L2P22 B1	-0.36	-0.35	-0.70	-0.68	550	18Y 31V 55V 72A
55	L5P16 H4	-0.37	-0.31	-0.69	-0.64	390	126K 73F 72A

[0116] Larger preparations of select probes were prepared for quantitative determination of binding affinities. Binding

isotherms were performed by measuring the fluorescence intensity for 1 μ M of a given probe as the probe was titrated with known quantities of UCB. A binding isotherm for the probe L2P14F7 (mutations: 18G 31M 72A) is shown in Figure 3. A non-linear fit to the data gives a K_d of 150 nM. Table 3 lists the K_d values and mutations for some example probes.

5 [0117] Initial screening of the UCB-probes indicated that the probes do not respond to FFA. This property was confirmed by titration of a mixture of 0.5 μ M UCB and 1 μ M L2P14F7 with sodium oleate. The probe shows no change in response even after 1 μ M total oleate has been added to the solution (Figure 4). Oleic acid is the most abundant FFA in serum, and measurements of normal serum samples indicate that typical unbound concentrations of oleic acid are less than 1 nM. By using non-responsive probes from FFA screening to conduct a secondary screening with other unbound analytes, a UCB-sensitive probe that has a negligible response to the major FFA in blood has been generated from a rI-FABP-L72A mutant.

10 [0118] The response of L2P14F7 to plasma samples from healthy adult donors, for which the UCBu concentration is expected to be about 1 nM or less, was measured (Figure 5). Samples were diluted to 1% by volume in pH 7.4 HEPES buffer. Little to no response was observed for these samples, indicating that no components within the plasma samples bind to L2P14F7 and alter its fluorescence. To demonstrate that the probe was still active, the samples were spiked with 5 μ M UCB, and the probe fluorescence was measured again. A substantial decrease in the fluorescence was observed for both samples A and B, corresponding to UCBu concentrations of 110 and 70 nM (Figure 3). An albumin assay revealed that sample B had a significantly greater serum albumin concentration than sample A, which is consistent with the lower levels of UCBu detected in sample B. The results demonstrate that L2P14F7 is a UCB-specific probe with no appreciable affinity for other typical serum components and that this probe can be used to measure pathophysiologic levels of UCBu in plasma.

20 [0119] It will be understood by those of skill in the art that numerous and various modifications can be made without departing from the spirit of the present invention. Therefore, it should be clearly understood that the forms of the present invention are illustrative only and are not intended to limit the scope of the present invention.

25

30

35

40

45

50

55

EP 2 385 375 A2

SEQUENCE LISTING

<110> Kleinfeld, Alan

5 <120> FLUORESCENT PROBES FOR HYDROPHOBIC ANALYTES

<130> FFASC.065PR

<160> 4

10 <170> FastSEQ for windows Version 4.0

<210> 1

<211> 399

<212> DNA

15 <213> Rattus norvegicus

<220>

<221> CDS

<222> (1)...(399)

20 <223> wild-type rat intestinal fatty acid binding protein cDNA sequence

<400> 1

atg gca ttt gat ggc act tgg aaa gta tac cgg aat gag aac tat gaa 48
Met Ala Phe Asp Gly Thr Trp Lys Val Tyr Arg Asn Glu Asn Tyr Glu
1 5 10 15

25 aag ttc atg gag aaa atg ggc att aac gtg gtg aag agg aag ctt gga 96
Lys Phe Met Glu Lys Met Gly Ile Asn Val Val Lys Arg Lys Leu Gly
20 25 30

30 gct cat gac aac ttg aaa ctg acg atc aca cag gaa gga aat aaa ttc 144
Ala His Asp Asn Leu Lys Leu Thr Ile Thr Gln Glu Gly Asn Lys Phe
35 40 45

aca gtc aaa gaa tca agc aac ttc cga aac att gat gtt gtg ttt gaa 192
Thr Val Lys Glu Ser Ser Asn Phe Arg Asn Ile Asp Val Val Phe Glu
50 55 60

35 ctc ggc gtc gac ttt gcc tat agt cta gca gat gga aca gaa ctc act 240
Leu Gly Val Asp Phe Ala Tyr Ser Leu Ala Asp Gly Thr Glu Leu Thr
65 70 75 80

40 ggg acc ttg acc atg gag gga aat aaa ctt gtt gga aaa ttc aaa cgt 288
Gly Thr Leu Thr Met Glu Gly Asn Lys Leu Val Gly Lys Phe Lys Arg
85 90 95

gta gac aat gga aag gag ctg att gct gtc cga gag att tct ggt aac 336
Val Asp Asn Gly Lys Glu Leu Ile Ala Val Arg Glu Ile Ser Gly Asn
100 105 110

45 gaa cta atc caa acc tac aca tat gaa gga gtg gag gcc aag cgc atc 384
Glu Leu Ile Gln Thr Tyr Thr Tyr Glu Gly Val Glu Ala Lys Arg Ile
115 120 125

50 ttt aag aag gaa tag 399
Phe Lys Lys Glu *

<210> 2

<211> 131

<212> PRT

55 <213> Rattus norvegicus

<220>

EP 2 385 375 A2

<221> PEPTIDE
 <222> (1)...(131)
 <223> wild-type rat intestinal fatty acid binding protein

5 <221> ACETYLATION
 <222> (1)...(1)

<400> 2
 Ala Phe Asp Gly Thr Trp Lys Val Asp Arg Asn Glu Asn Tyr Glu Lys
 1 5 10 15
 Phe Met Glu Lys Met Gly Ile Asn Val Val Lys Arg Lys Leu Gly Ala
 20 25 30
 His Asp Asn Leu Lys Leu Thr Ile Thr Gln Glu Gly Asn Lys Phe Thr
 35 40 45
 Val Lys Glu Ser Ser Asn Phe Arg Asn Ile Asp Val Val Phe Glu Leu
 50 55 60
 Gly Val Asp Phe Ala Tyr Ser Leu Ala Asp Gly Thr Glu Leu Thr Gly
 65 70 75 80
 Thr Trp Thr Met Glu Gly Asn Lys Leu Val Gly Lys Phe Lys Arg Val
 85 90 95
 Asp Asn Gly Lys Glu Leu Ile Ala Val Arg Glu Ile Ser Gly Asn Glu
 100 105 110
 Leu Ile Gln Thr Tyr Thr Tyr Glu Gly Val Glu Ala Lys Arg Ile Phe
 115 120 125
 Lys Lys Glu
 130

25 <210> 3
 <211> 426
 <212> DNA
 <213> Rattus norvegicus

30 <220>
 <221> mutation
 <222> (1)...(426)
 <223> rat intestinal fatty acid binding protein DNA
 sequence coding for substitution of alanine for
 leucine at position 72

35 <223> 3' terminus codes for a 6his tag

<400> 3
 atggcatttg atggcacttg gaaagtagac cggaatgaga actatgaaaa gttcatggag 60
 aaaatgggca ttaacgtggt gaagaggaag ctggagctc atgacaactt gaaactgacg 120
 atcacacagg aaggaaataa attcacagtc aaagaatcaa gcaacttccg aaacattgat 180
 gttgtgtttg aactcggcgt cgactttgcc tatagtgtg cagatggaac agaactcacc 240
 40 ggtacctgga caatggaggg aaataaactt gttggaaagt ttaaactgtg agacaatgga 300
 aaggagctga ttgctgtccg agagatttct ggtaacgaac taatccagac ctacacatat 360
 gaaggagtgg aggccaagcg gatctttaag aaggaccgcg gtcacatca ccatcatcac 420
 tagtaa 426

45 <210> 4
 <211> 139
 <212> PRT
 <213> Rattus norvegicus

50 <220>
 <221> MUTAGEN
 <222> (72)...(72)
 <223> rat intestinal fatty acid binding protein with
 alanine substitution for leucine at position 72

<223> 6His tag at N terminus

55 <400> 4
 Ala Phe Asp Gly Thr Trp Lys Val Asp Arg Asn Glu Asn Tyr Glu Lys
 1 5 10 15

EP 2 385 375 A2

Phe Met Glu Lys Met Gly Ile Asn Val Val Lys Arg Lys Leu Gly Ala
 His Asp Asn Leu Lys Leu Thr Ile Thr Gln Glu Gly Asn Lys Phe Thr
 5 Val Lys Glu Ser Ser Asn Phe Arg Asn Ile Asp Val Val Phe Glu Leu
 Gly Val Asp Phe Ala Tyr Ser Ala Ala Asp Gly Thr Glu Leu Thr Gly
 65 Thr Trp Thr Met Glu Gly Asn Lys Leu Val Gly Lys Phe Lys Arg Val
 10 Asp Asn Gly Lys Glu Leu Ile Ala Val Arg Glu Ile Ser Gly Asn Glu
 Leu Ile Gln Thr Tyr Thr Tyr Glu Gly Val Glu Ala Lys Arg Ile Phe
 Lys Lys Asp Arg Gly His His His His His His
 15 130 135

Claims

1. An iLBP capable of binding an unbound metabolite and having a value of $\Delta R/\Delta R_{ADIFAB2}$ which is < 0.1 for unbound fatty acids but is > 0.1 for an unbound metabolite that is not a fatty acid.
2. A protein mutein of SEQ ID NO: 2 comprising a substitution at position 72 of SEQ ID NO: 2 and comprising at least 2 additional substitutions, wherein the protein mutein exhibits $AR/AR_{ADIFAB2}$ which is < 0.1 for unbound fatty acids.
3. The iLBP of claim 1 or the protein mutein of claim 2, which has negligible or no binding to free fatty acids (FFA).
4. The iLBP of claim 1 or the protein mutein of claim 2 or 3, comprising a substitution at position 117.
5. The iLBP of claim 1 or the protein mutein of claim 2 or 3, comprising a substitution at position 31.
6. The iLBP of claim 1 or the protein mutein of any of claims 2, 3 or 5, comprising a substitution at position 18.
7. The iLBP of claim 1 or the protein mutein of any of claims 2-6, comprising 2-4 substitutions.
8. A probe selected from the group consisting of L2P14F7, L5P16H4, L1P1C12, L1P12E8 and L1P14D6.
9. The iLBP of any of claims 1-7 or the protein mutein of any of claims 2-7 or the probe of claim 8, which binds bilirubin.
10. The iLBP of claim 1 or the protein mutein of any of claims 2-7 which is fluorescently labeled.
11. A method to determine the concentration of unbound bilirubin in body fluids of a mammal which comprises:
 - withdrawing a body fluid from the mammal;
 - contacting the body fluid with the labeled iLBP or the labeled protein mutein of claim 10 or a probe of claim 8; and
 - determining the level of unbound bilirubin by measuring binding to the probe and comparing to a standard.
12. A probe selected from the group consisting of probes listed in Tables 3-7.
13. A method of determining a profile of unbound metabolites in body fluids for an individual which comprises measuring the concentrations of unbound metabolites with a combination of probes produced by a high throughput method for generating and screening of probes comprising the steps of:
 - generating polynucleotides encoding a protein library comprising an assortment of proteins which are mutations of a template Fatty Acid Binding protein (FABP) capable of binding to an unbound metabolite participating in a binding reaction wherein the unbound metabolite is not a free fatty acid;
 - expressing the proteins;

EP 2 385 375 A2

purifying the proteins by binding to a solid matrix;
associating the matrix bound proteins with fluorophores to produce probes;
retrieving the probes from the solid matrix; and
screening the probes in a fluorometer in the presence and absence of the unbound metabolite.

- 5
- 14.** The method of claim 13, wherein the body fluid is selected from the group consisting of whole blood, blood plasma, blood serum, urine, CSF, saliva, gastric juices, interstitial fluid, synovial fluid and lymph.
- 10
- 15.** A polynucleotide comprising a nucleotide sequence encoding a functional engineered protein which is a fluorescently labeled FABP with at least one mutation which has a value of $\Delta R/\Delta R_{ADIFAB2}$ with an unbound free fatty acid which is less than 0.1 but is > 0.1 for an unbound metabolite that is not a fatty acid.
- 15
- 20
- 25
- 30
- 35
- 40
- 45
- 50
- 55




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 5470714 A [0007] [0065]
- US 6444432 B [0007]
- US 10670958 B [0065]
- US 2004030521 W [0065]
- US 670958 A [0112]

Non-patent literature cited in the description

- HAUNERLAND et al. *Progress in Lipid Research*, 2004, vol. 43, 328-349 [0006]
- RICHIERI et al. *Biochemistry*, 2000, vol. 39, 7197-7204 [0006]
- JAKOBY et al. *Biochemistry*, 1993, vol. 32, 872-878 [0006]
- BANASZAK et al. *Adv. Protein Chem.*, 1994, vol. 45, 89-151 [0007]
- BERNLOHR et al. *Ann. Rev. Nutrition*, 1997, vol. 17, 277-303 [0007]
- DEMANT, E. *Anal. Biochem.*, 1997, vol. 267, 366-372 [0064]
- MASSEY, J.B. et al. *Biophys. J.*, 1996, vol. 72, 1732-1743 [0064]
- RICHIERI, G.V et al. *J. Biol. Chem.*, 1992, vol. 276, 23495-23501 [0065]
- APPLE et al. *Clinical Proteomics*, 2004, vol. 1, 41-44 [0065] [0112]
- RICHIERI et al. *Molecular and Cellular Biochemistry*, 1999, vol. 192, 87-94 [0101] [0107]
- RICHIERI et al. *J. Biol. Chem.*, 1996, vol. 271, 31068-31074 [0101]
- RICHIERI ; KLEINFELD. *J. Lipid Res.*, 1995, vol. 36, 229-240 [0112]

专利名称(译)	开发和使用未结合分析物的荧光探针		
公开(公告)号	EP2385375A2	公开(公告)日	2011-11-09
申请号	EP2010177671	申请日	2005-03-21
申请(专利权)人(译)	FFA科学, 律师事务所		
当前申请(专利权)人(译)	FFA科学, 律师事务所		
[标]发明人	KLEINFELD ALAN MARC HUBER ANDREW HENRY KAMPF JAMES PATRICK ZHU BAOLONG KWAN THOMAS		
发明人	KLEINFELD, ALAN, MARC HUBER, ANDREW, HENRY KAMPF, JAMES, PATRICK ZHU, BAOLONG KWAN, THOMAS		
IPC分类号	G01N33/92 G01N33/58 G01N33/533 G01N33/72 C12P19/34 C12P21/02 C12Q1/68		
CPC分类号	C12P21/02 G01N33/533 G01N33/582 G01N33/728		
优先权	60/555224 2004-03-22 US		
其他公开文献	EP2385375A3		
外部链接	Espacenet		

摘要(译)

描述了用于探针的高通量筛选的方法。这些探针可用于表征和测量流体样品中未结合的代谢物，特别是表征和测量未结合的游离脂肪酸的水平。通过实施所公开的发明，可以确定个体的未结合代谢物的概况，其可以用于确定个体的疾病相对风险，例如中风，心脏病和癌症。




FIG. 1